Document:

EX-10.17

 Exhibit 10.17 
 [ ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the
Securities Act of 1933, as amended. 
 DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT 

BETWEEN 

DUOJECT MEDICAL SYSTEMS INC. 
 50 de Gaspé Street, Complex B-5 
 Bromont, Quebec, Canada 

J2L 2N8 
 AND

 REVANCE THERAPEUTICS, INC. 
 7555 Gateway Blvd. 
 Newark, CA 94560 

USA 

  
 1 

 THIS AGREEMENT (the “Agreement”) is entered into as of April 30, 2010 

 

			
	BY AND BETWEEN:	  	DUOJECT MEDICAL SYSTEMS INC., a corporation incorporated according to the laws of Canada, having its registered office at 50 de Gaspé Street, Complex B-5, Bromont,
Province of Quebec, Canada, J2L 2N8
		
		  	Hereinafter called “DUOJECT”
		
	AND:	  	REVANCE THERAPEUTICS, INC., a company duly organized and existing under the laws of Delaware, with its principal offices located at 7555 Gateway Blvd., Newark, State of
California, U.S.A. 94560
		
		  	Hereinafter called “REVANCE”
		
		  	REVANCE and DUOJECT shall each be referred to as a “Party” and jointly as “Parties”.

 WHEREAS, DUOJECT agrees to use its best efforts to develop, manufacture and supply components to be used in conjunction
with a Reconstitution/Application Apparatus according to the specifications contained in the Product Design Specifications attached hereto as Annex “A” (hereinafter referred to, and further defined below as the “RAA”) and
further as appears from a sketch of the RAA set out therein as Figure 1. 
 WHEREAS, DUOJECT agrees that REVANCE shall have the exclusive right
to sell and distribute and to have the RAA assembled by a third party so that the RAA can be commercialized to be used with topical neuromuscular paralytic agents. 
 NOW THEREFORE, in consideration of the above covenants and mutual promises herein contained, the Parties agree as follows: 
 ARTICLE I – DEFINITIONS 
  

	1.1	As used in this Agreement, each term listed below shall have the meaning that is given after it: 

“Accessories” shall mean the components not supplied by DUOJECT but by any other independent entity hired by REVANCE and
used in conjunction with the RAA. 
 “Affiliate(s)” shall mean any corporation, firm, partnership or other
legal entity that, directly or indirectly, is controlled by, is in control of or under common control with the Party in question, but only for so long as such control continues to exist. For the purpose of this Agreement “control” means
ownership of over fifty percent (50%) of the equity having the power to vote on or otherwise direct the affairs of the entity. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2 

 “Applicable Law” shall mean all laws applicable to the manufacture,
processing, marketing, and distribution of the RAA, including, without limitation, the U.S. Federal Food, Drug, and Cosmetic Act, as amended, and the regulations promulgated thereunder, including all applicable principles and guidelines of good
manufacturing practices; and all other corresponding laws, ordinances, rules and regulations of any other applicable jurisdiction. 
 “Binding Period” has the meaning set out in Section 6.2 hereof. 
 “Business Days” means Monday through Friday inclusive, save and except for any legal holidays constituted as such in the Province of Quebec which occurs on any such week day. 

“Confidential Information” has the meaning set out in Section 12.8. 

“Development Work” has the meaning attributed to it in Section 2.1 hereof. 

“Duoject IP” shall mean all patentable and non-patentable inventions, Intellectual Property, discoveries, improvements,
modifications, data, trade secrets, know-how and any equivalence thereof which are generated by DUOJECT during the Term hereof and in accordance with this Agreement and which shall include, but is not limited to, pending patent applications and any
amendment provisional or further modifications thereof. 
 “Effective Date” means the date of the signature of
this Agreement. 
 “Election Date” has the meaning set out in Section 3.1 hereof. 

“Field” means topical neuromuscular paralytic agents. 

“Flexible Period” has the meaning set out in Section 6.2 hereof. 

“Information” means any and all information, data or result which is in the possession of or available to REVANCE or its
affiliates and/or DUOJECT or its affiliates necessary or useful in the evaluation, manufacturing, placing on the market, and obtaining of approvals with relevant regulatory bodies of the RAA in connection with the Field. 

“Intellectual Property” means and includes, without limitation, all discoveries, developments, ideas, concepts, work of
authorship, trade secrets, rights in patents, patent applications, formulae, trade-marks, trade-mark applications, trade-names, inventions, copyright, industrial designs and all other intellectual and industrial property rights of any sort
throughout the world now known or hereafter recognized. 
 “Lot” means a specific quantity of RAAs manufactured
pursuant to a single, continuous process run as specified in a purchase order of REVANCE. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 3 

 “Material Breach” means a breach by DUOJECT of its obligations under this
Agreement which a reasonable person conversant with the industry and markets in which the Parties are involved would deem to be of sufficient seriousness so as to deprive REVANCE of the material benefits expected from this Agreement or affect the
ability of REVANCE to carry out its planned business activities or obligations with regard to third parties. 
 “Outside
Date” means the date attributed in Section 7.1 
 “PDS” shall mean the Product Design
Specifications document attached hereto as Annex “A”. 
 “Quality System Regulation” means the
quality system regulation for medical devices, as defined in 21 C.F.R. Part 820, as amended from time to time, or a foreign equivalent thereof. 
 “RAA” means the single use, Reconstitution/Application Apparatus developed by DUOJECT as described in Annex “A”. 

“Registration” means approvals required by any authority or regulatory bodies, necessary to market, distribute and use
the RAA in the Territory pursuant to this Agreement during the Term of this Agreement. 
 “Specifications”
means: (i) the technical and quality parameters included in the PDS to which the parties agree to constitute acceptable standards for the manufacture of the RAA; and (ii) regulatory requirements applicable to the RAA if and when the RAA is
marketed or used in the Field all of which may be updated or amended from time to time. These Specifications are valid for the USA. Other countries/markets may require new or modified Specifications to meet legal or regional regulatory requirements
to market the RAA, in which event the parties shall mutually agree on the terms and conditions of any such modifications, but any additional required work shall be performed at reasonable rates as specified in Annex “E”. 

“Term” has the meaning as set out in Section 10.1. 

“Territory” means the World. 
 “Trigger Event” means: 1) a Failure to Supply (as defined in Section 6.5); or 2) REVANCE terminates the Agreement in accordance with Sections 10.2, 10.3 or 10.4. 

ARTICLE II – DEVELOPMENT WORK 
  

	2.1	DUOJECT shall use its best business efforts to develop the RAA in accordance with the terms and conditions of this Agreement and as more fully described and set
out in Annex A, Annex B and Annex C (the “Development Work”). 

  

	2.2	DUOJECT shall use its best business efforts to achieve the deliverables listed in Annex A following the project timeline shown in Annex B.

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 4 

	2.3	REVANCE acknowledges that the RAA and any device-related improvements, modifications or change that may arise therefrom are and will remain DUOJECT IP. The RAA
contains Information which is confidential and proprietary to DUOJECT. Notwithstanding the foregoing, DUOJECT acknowledges that both DUOJECT and REVANCE have joint ownership of the Intellectual Property reflected in the patent application which was
made on the 30th day of October, 2009 with the US Patent Office and bears Application Number 61256837. In addition, the parties shall jointly own all right, title and interest (including all related intellectual property rights) in and to any
Invention that is conceived or developed jointly by employees or consultants of both parties (collectively with the above-referenced patent, “Joint IP”). Each party shall have the right to non-exclusively license and otherwise fully
exploit all Joint IP without further consent of or accounting to the other party; provided that DUOJECT’s rights in Joint IP shall be subject to the exclusive licenses granted to REVANCE in this Agreement. Each party shall ensure that it has
agreements with its employees and contractors sufficient to allow it to effectuate the foregoing ownership of joint rights of the Joint IP. No other rights or licenses are granted by either party except as expressly set forth in this Agreement, and,
for clarity, REVANCE grants no rights or licenses regarding Intellectual Property which may be developed by REVANCE. 

  

	2.4	In due consideration for the Development Work and all other services performed by DUOJECT and the rights granted to REVANCE under this Agreement, REVANCE agrees
to pay DUOJECT the amount not exceeding that quoted in Annex “C”, such compensation being in the form of agreed milestone payments. DUOJECT shall notify REVANCE upon successful completion of each milestone. A milestone will be presumed to
be accepted by REVANCE unless it objects in writing within thirty (30) days after DUOJECT’S notification, such objection to specify the reasons for non-acceptance. DUOJECT shall invoice REVANCE upon successful completion (and acceptance)
of each milestone in accordance with Annex “C”. REVANCE shall pay such invoices within thirty (30) days after receipt of the invoice, unless such milestone has not been accepted as set forth above in good faith. Each invoice shall
reference the applicable milestone and be denominated in United States currency. REVANCE agrees that DUOJECT shall not be responsible for any delay in the Development Work resulting from a delay of payment by REVANCE. No additional charges or fees
are binding on REVANCE unless approved in writing by REVANCE and then only if notified according to this Section 2.4. 

  

	2.5	The terms of this Agreement, including, but not limited to the milestone dates and the specific tasks to be completed as part of the Development Work, may only
be modified by means of a written document signed by REVANCE and DUOJECT. REVANCE may make changes within the general scope of the Development Work by means of a written change order. If any change order causes an increase or decrease in the cost
of, or the time required for, the performance of the Development Work, DUOJECT will notify REVANCE in writing within thirty (30) days and request that a reasonable adjustment be made to the milestone date and/or amount payable and provide
appropriate supporting documentation; provided that such changes shall be made at no additional charge to REVANCE if it relates to DUOJECT’s fault or negligence. Any adjustment shall be mutually agreed in writing, but any such work shall be
performed at reasonable rates as specified in Annex “E”. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5 

	2.6	DUOJECT shall at all times during the term of this Agreement dedicate an experienced team of designers including one senior project manager. DUOJECT shall
appoint a senior project manager to serve as the single point-of-contact and liaison between DUOJECT and REVANCE for Development Work. The project manager will be responsible for the coordination of all Development Work. 

 

	2.7	DUOJECT shall keep REVANCE fully informed of the status of the Development Work. DUOJECT shall provide to REVANCE on a regular basis summary reports which shall
include progress and results of the Development Work, a description of any issues encountered in meeting milestones, and if any issues are encountered, proposed recovery methods. 

ARTICLE III – RIGHTS AND OBLIGATIONS 
  

	3.1	Subject to the provisions hereof, DUOJECT hereby grants to REVANCE an exclusive, worldwide, sub-licensable license (subject to DUOJECT’s prior written
approval (for sublicensing) which shall not be unreasonably withheld) to use, distribute, sell, offer for sale, import and deliver the RAA for use in the Field and in the Territory during the Term of this Agreement under REVANCE’s brand name
provided that DUOJECT’S name as the manufacturer of the RAA is also displayed on the RAA in a reasonable manner and location. Subject to the next following sentence, DUOJECT agrees that neither it nor its Affiliates shall during the Term (nor
shall any of them authorize or support any third party to), directly or indirectly, make, use, distribute, sell, offer for sale, import or otherwise exploit in the Field the RAA, any improvements, modifications, or derivatives thereof or successors
thereto, or any device that performs substantially the same function in a similar manner. In the event that the RAA is not made commercially available within [***] of U.S. regulatory approval or within [***] from the effective date of this
Agreement, whichever date shall first occur (the “Election Date”), the following terms shall apply. If, upon the occurrence of the Election Date, REVANCE has not made the RAA commercially available, REVANCE shall have the option (within 30
days after the Election Date) of: (i) terminating this Agreement upon written notice to DUOJECT; or (ii) electing by written notice to DUOJECT to continue the Agreement on a year to year basis in accordance with the following provisions of
3.1.1 and 3.1.2: 

  

	 	3.1.1	Should the RAA not be commercially available by the Election Date and should REVANCE elect to continue the Agreement, then for the first year commencing from the
Election Date, REVANCE shall accompany the notice to that effect with a payment of [***] Dollars ($[***] USD). For each subsequent year thereafter, if the RAA is not yet commercially available, the same election process shall apply, but during each
such year REVANCE will instead be required to purchase the minimum RAA units set forth in Section 6.7 to maintain this Agreement in effect for the corresponding year (but, for purposes of determining such minimums, the parties shall treat the
second year after the Election Date as if it were the second year after first commercial sale described in that Section and all subsequent years shall be treated in a corresponding manner). 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6 

	 	3.1.2	When the RAA becomes commercially available to the public, the provisions of section 6.7 of the Agreement shall apply. For purposes of determining which yearly
annual minimum threshold applies under Section 6.7 thereafter, each year by which Revance extended this Agreement under Section 6.1 above shall be deemed to be a year in which Revance had made commercial sales of the RAA. For example, if
Revance had extended the Agreement for two full years after the initial Election Date prior to making a commercial sale, then the applicable annual minimum for purposes of Section 6.7 for the following year would be deemed to be the amount
applicable to the [***] year of minimums specified in Section 6.7 (or [***] RAA units). 

  

	3.2	REVANCE shall not use, distribute and sell the RAA for use with any other compound other than as described in the Field. Should REVANCE wish to use, distribute
and sell the RAA for use with any compound outside the Field, a separate agreement shall be entered into by the Parties which shall be subject to their mutual agreement. 

 

	3.3	DUOJECT represents, warrants, and covenants that it shall (i) provide the services under this Agreement in a professional, workmanlike and diligent manner,
including but not limited to packaging and supply of the RAA in accordance with: (a) Quality System Regulations; (b) the Specifications; (c) any other terms or conditions herein; and (d) all applicable laws, rules, and
regulations. 

  

	3.4	As set out in Annex C, REVANCE acknowledges that specialized or dedicated equipment is required to manufacture the RAA for REVANCE. The different equipment
options and estimated costs associated with the purchase, installation and validation of such equipment is as set out in the attached Annex C. DUOJECT agrees to install and validate the equipment offered by DUOJECT and selected by REVANCE and shall
bill REVANCE for the associated pre-approved costs for such selected equipment. REVANCE shall make such payment to DUOJECT no later than thirty (30) days after REVANCE receives an invoice from DUOJECT. Title to the equipment shall be in
REVANCE’s name and shall be maintained free of any liens, claims, encumbrances, or the like. If DUOJECT wishes to use the specialized or dedicated equipment for manufacture of a product other than the RAA for REVANCE, DUOJECT and REVANCE shall
meet and discuss the technical and practical ramifications of such use and appropriate compensation to REVANCE. Any such use shall be subject to REVANCE’s prior written approval. 

ARTICLE IV – PDS / SPECIFICATIONS / REGISTRATION DESCRIPTION 

 

	4.1	Both parties agree to promptly notify each other in writing of any requested change in the Specifications for the RAA that may be required or necessary to comply
with any legal or regulatory requirement during the Term of this Agreement. REVANCE acknowledges that DUOJECT may from time to time advise REVANCE of recommended changes to the RAA because of manufacturing and other similar reasons.

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7 

	4.2	DUOJECT agrees to make every effort to make the modifications requested by REVANCE to the Specifications provided such modifications are technically feasible and
that, the duration of development proposed by DUOJECT (using best efforts to complete such development as soon as feasible) with respect to such modifications is accepted by REVANCE and that REVANCE pays DUOJECT for all costs and expenses incurred
in meeting such modifications under request at reasonable time and materials rates as specified in Annex “E”. REVANCE acknowledges that DUOJECT may increase the price referred to in this Agreement in the Annexes attached hereto as a result
of any such agreed modification to reflect the foregoing. 

  

	4.3	DUOJECT shall within forty-five (45) days from REVANCE’s request notify REVANCE of such additional costs, expenses, changes to time lines and charges
as such changes would entail along with supporting documentation. 

  

	4.4	If DUOJECT is not able to make the modifications that REVANCE has requested in accordance with the foregoing section, the provisions of this Agreement shall
continue until the Parties have arrived at a mutual agreeable decision as to any future course of events provided that, should the Parties not be able to agree within thirty (30) days, DUOJECT agrees that REVANCE may terminate this Agreement in
which event, REVANCE agrees that it shall have no license hereunder to exploit, use, market or sell any RAA or other item which incorporates DUOJECT IP and shall otherwise be bound by the provisions of Article X hereof. 

 

	4.5	DUOJECT undertakes not to modify the Specifications without first having received the prior written approval of REVANCE. 

 

	4.6	Subject to Section 4.2, neither Party will have any obligation under any requested change unless and until such change is mutually agreed upon in writing by
the Parties. 

 ARTICLE V – RAA REGISTRATION 

 

	5.1	REVANCE shall be responsible for obtaining registrations for the RAA relevant to the Field in the Territory. As between the parties, REVANCE shall be responsible
for complying with and submitting any and all regulatory documentation, test results, test specifications, documentation and information to the relevant authorities in order to obtain the necessary clearance to allow REVANCE’s use of the RAA in
the Field and in the Territory. 

  

	5.2	 DUOJECT agrees to provide REVANCE with such Information and all assistance as necessary in obtaining any and all registration for the use of the
RAA and exercise of REVANCE’s rights hereunder in the Territory (including, without limitation, promptly reviewing and, to the extent that it is within. DUOJECT’s ability to do so, providing feedback on those portions of REVANCE’s
proposed regulatory submissions relating to DUOJECT’s manufacturing or packaging procedures) for the fee specified in Annex “C”. Should DUOJECT subsequently provide any additional documentation and/or information not contemplated by
Annex C, DUOJECT shall prior to proceeding, provide a cost proposal for such additional work. REVANCE shall be the sole owner of any 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8 

 
regulatory submission filed pursuant to this Agreement. All of DUOJECT’s obligations under this Article V shall be performed using appropriately skilled personnel with relevant experience.

 ARTICLE VI – SUPPLY AND DELIVERY 
  

	6.1	Subject to Section 3.1, DUOJECT agrees to supply REVANCE on an exclusive basis with its requirements of the RAA at the prices and upon the terms and
conditions specified herein. Without limiting Section 6.5, nothing in this Agreement shall limit REVANCE’s right, in its discretion, to buy products similar or equivalent to the RAA from any third party during the Term of this Agreement,
but this sentence is not intended to grant (and does not grant) REVANCE (or any third party) any license to (or other rights to infringe or use) DUOJECT’s IP in connection with such third party activities. REVANCE acknowledges that the RAA
incorporates DUOJECT’s IP as well as that which is contained in the device marketed publicly by DUOJECT and known as the Inter-Vial, and consequently that DUOJECT is not restricted by this Agreement in the supply, sale, distribution or
manufacture of the DUOJECT Inter-Vial to any third party outside of the Field. 

  

	6.2	REVANCE shall provide DUOJECT with a 12-month rolling forecast during which the first six (6) months shall be considered binding on both Parties (the
“Binding Period”) and the remaining six (6) months being considered non-binding and illustrative only and subject to modification by REVANCE (the “Flexible Period”) REVANCE shall place purchase orders for the
RAA at least one hundred and thirty-five (135) days prior to delivery. DUOJECT shall acknowledge its acceptance of such Purchase Orders within ten (10) working days; DUOJECT may only reject that portion of a Purchase Order that calls for
the delivery of RAA in less than one hundred and thirty-five (135) days after the Purchase Order was received by DUOJECT and it is not commercially feasible for DUOJECT to deliver such RAA in the requested timeframe. Purchase Orders shall
indicate the quantity, delivery date, delivery country and address to which the relating invoice for the RAA shall be sent. For the first three (3) years of this Agreement, any purchase orders from REVANCE may vary by the greater of
(a) +/- 50% from the provided corresponding Flexible Period forecast, and (b) [***] units of the RAA, without any financial consequences to REVANCE, and DUOJECT will use its best efforts to address this initial production period. For
future years, any purchase order emanating from REVANCE which vary by more than +/- 25% from the quotation relating to the Flexible Period forecast shall be subject to DUOJECT’s written approval within ten (10) business days (which shall
not be unreasonably withheld). For clarity, to the extent DUOJECT is able to fulfill orders outside the limits provided in this Section there shall be no charges or penalties to REVANCE (other than the per unit price for the additional units
ordered). 

  

	6.3	DUOJECT shall deliver the RAA to REVANCE ex works (Incoterms 2000) following receipt of REVANCE’s Purchase Order (and on the delivery dates set forth
therein), subject to Section 6.2. Each shipment of the RAA shall be accompanied by the agreed documentation set forth in the Specifications including, but not limited to DUOJECT’s certificate of conformity that the shipment of the RAA
meets the Specifications. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9 

	6.4	DUOJECT shall keep complete and accurate records reflecting all information necessary or useful in verifying its manufacturing procedures and specifications and
any charges that may be billed to REVANCE hereunder on a time and materials basis (if any), and all other records relevant to DUOJECT’s performance hereunder as required by Applicable Law. REVANCE may visit the premises where the RAAs are being
manufactured for and/or on behalf of REVANCE at mutually agreed times and review DUOJECT’s manufacturing operations relating to the RAA during regular business hours after having provided at least five (5) Business Days notice to DUOJECT
to permit REVANCE to verify compliance by DUOJECT with the Specifications, Applicable Law and quality assurance standards and general compliance by DUOJECT with its obligations under this Agreement and to discuss any related issues with
DUOJECT’s manufacturing and management personnel. DUOJECT shall bear the costs of any audit if DUOJECT has breathed this Agreement. DUOJECT shall provide REVANCE with copies of DUOJECT’s manufacturing records relating to the RAA for the
purposes of assuring the RAA’s quality and compliance with agreed-upon manufacturing procedures. DUOJECT also agrees to allow the FDA to conduct any audit which the FDA requires and DUOJECT agrees to reasonably cooperate with the FDA in
connection with such audit. DUOJECT shall provide prompt notice to REVANCE of any audit or inspection involving the FDA, and REVANCE shall have the right to accompany such auditors and participate in any such audit and/or inspection.

  

	6.5	Subject to article 12.1, in the event that DUOJECT is unable or unwilling to manufacture or supply the RAA in accordance with REVANCE’s purchase orders
(“Failure to Supply”) or another Trigger Event occurs, REVANCE may establish a licensed second source for the manufacture and supply of the RAA and DUOJECT shall cooperate and assist REVANCE in such transition (including without
limitation, providing all specialized tooling, molds (which belong to REVANCE), data, know-how and other information related to DUOJECT’s manufacturing process with respect to the RAA (“Transition Information”)). In connection
with a Failure to Supply or other Trigger Event and/or any supply transition under Section 12.1, DUOJECT hereby grants REVANCE an exclusive, perpetual, irrevocable, royalty-bearing, sublicensable right and license in the Field, under
DUOJECT’s intellectual property rights, to make and have made, use, sell, offer for sale and import the RAA and any improvements, modifications or derivatives thereof or successors thereto. Without limiting the foregoing license grant, the
parties agree to memorialize a long form license agreement (“License Agreement”) that will contain, but will not be restricted to, substantially the following terms (if Failure to Supply or another Trigger Event occurs):

  

	 	6.5.1	an undertaking by REVANCE that it will actively market the RAA; 

  

	 	6.5.2	a minimum annual payment that is creditable against royalties with respect to units of RAA sold, distributed and/or manufactured by REVANCE of [***] U.S. Dollars
($[***]), payable in quarterly installments on the first day of each quarter, commencing on the first day of the third month following the month in which the RAA becomes commercially available to the public (the “Minimum Royalty”);

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10 

	 	6.5.3	an undertaking by REVANCE to pay each quarter subject to applying a credit against the Minimum Royalty a running royalty which will commence with the first day
of the first quarter of the term of the License Agreement for each unit of the RAA sold by or for REVANCE or by or for a permitted sub-licensee of REVANCE in accordance with the following royalty schedule; 

 

			
	 Annual Volume
	  	 Royalty

	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  

	 	6.5.4	provisions dealing with the proper recording of all sales of the RAA; 

 

	 	6.5.5	provisions regarding the respective contributions of each of the parties in defending or prosecuting patent infringements or allegations hereof;

  

	 	6.5.6	an acknowledgement by REVANCE and DUOJECT to immediately notify the other of any improvement that each may discover, make, develop or be advised of relating to
the RAA. In the event that the License Agreement is still in effect, then any such improvement shall be included in the exclusive license granted to REVANCE without any additional consideration or royalty payment. Any device-related improvement to
the RAA whether derived from DUOJECT or REVANCE shall be owned by, and be the property of DUOJECT (subject to the license agreement being in effect); 

  

	 	6.5.7	provisions incorporating all of the terms and conditions of the confidentiality provisions contained herein and in any previous agreements respecting
confidentiality previously signed by both parties; 

  

	 	6.5.8	undertaking by REVANCE shall undertake that it will not at any time during or after the term of the License Agreement dispute or attack the validity of any
patent which has or may be granted to DUOJECT for the DUOJECT IP, nor will REVANCE assist or help others in such dispute or attack; 

  

	 	6.5.9	a provision that any dispute between the parties shall be finally settled by arbitration in accordance with the provisions of Article XI of the Agreement;

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11 

 The parties shall use reasonable efforts to memorialize the License Agreement, using custom and usage as a
guide and acting reasonably and in good faith, within six (6) months after the commencement of negotiations. However, the failure to execute a License Agreement for any reason shall not limit REVANCE’s right to exploit the RAA under the
license granted in Section 6.5 provided REVANCE continues to pay the Royalties and the minimum Royalty described in Sections 6.5.2 and 6.5.3. 
  

	6.6	In the event (i) any regulatory authority or other national government authority issues a request, directive or order that the RAA be recalled for reasons
related to the RAA; (ii) a court of competent jurisdiction orders such a recall, or (iii) REVANCE reasonably determines that the RAA requires a recall, the parties shall take all appropriate corrective actions, and shall cooperate in any
governmental investigations surrounding the recall. In the event that such recall results from the breach of DUOJECT’s warranties or otherwise from DUOJECT’s fault, DUOJECT agrees that it shall be responsible for promptly replacing those
RAAs that were the cause of the recall at no cost to REVANCE. In addition, in such event, DUOJECT agrees that it shall be responsible for the reasonable expenses of any recall with respect to including notification and destruction or return of the
recalled RAA and any costs associated with the distribution of the replacement RAA up to a cap of $[***] per recall. REVANCE shall bear the costs associated with any recall resulting from the fault of REVANCE. 

 

	6.7	For each year during the Term starting from the day that the RAA becomes commercially available to the public, REVANCE covenants and agrees to purchase from
DUOJECT not less than the minimum purchase quotes set forth in the table below: 

  

			
	 Year
	  	 Minimum RAA Unit Purchase

	 First
	  	[***]
	 Second
	  	[***]
	 Third
	  	[***]
	 Fourth
	  	[***]
	 All subsequent years of the Term
	  	[***]

 ARTICLE VII – PAYMENT 

 

	7.1	 The incremental prices specified in Annex “D” shall remain in effect until product approval or no later than [***], (the
“Outside Date”), whichever date shall first occur. For each year following the Outside date during the Term of this Agreement, the price of the RAA shall be increased or decreased as the case may be on the basis of the cost of oil
(and specifically its effect on the cost of resin used in production of the RAA, but the increase or decrease in price shall only be in proportion to the cost of resin as a percentage of the overall cost of the RAA) in effect as of the date hereof
plus or minus the increase (or decrease) in the cost of living average of the immediately preceding calendar year as reflected by the Wholesale Price Index of the U.S. Department of Labor’s Bureau of Labor Statistics for all commodities or if
said index is no longer being published, then another index generally recognized as authoritative shall be substituted by agreement and if the Parties should not agree, such substituted index shall be selected by the then presiding judge of the
Superior Court of the State of Delaware by the application 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12 

	 	
of either Party. Such increase or decrease may occur only [***] in each twelve (12) month period, following ninety (90) days prior written notice to REVANCE. Any price increases shall
only be effective for Purchase Orders submitted following the applicable price increase. If applicable laws or regulations require that any withholding taxes be withheld from amounts payable to DUOJECT hereunder, REVANCE will (i) be entitled to
deduct those taxes from all remittable payments, (ii) timely pay the taxes to the proper taxing authority, and (iii) send proof of payment to DUOJECT after receipt of confirmation of payment from the relevant taxing authority.

  

	7.2	Each supply of RAA supplied by DUOJECT pursuant to the terms and conditions hereof shall be invoiced separately by DUOJECT. Invoices shall not be issued earlier
than the date of issue of the certificate of conformity and shall cite the purchase order number of REVANCE, the quantity of such delivery and shall be addressed to the Finance Department of REVANCE. REVANCE shall make payment to DUOJECT within
thirty (30) days of the receipt by REVANCE of the invoice. All payments shall be made in US currency by bank draft or wire transfer. 

  

	7.3	REVANCE agrees to pay DUOJECT for the RAAs delivered, pursuant to section 7.2, in accordance with the incremental prices set out in Annex D. Pricing will be
calculated on the quantity purchased during each 12 month period starting with the first delivery. Quantity price reductions shall apply only to the quantity purchased within each price level. At the end of each twelve (12) month period, total
purchase quantity will be calculated and DUOJECT shall issue to REVANCE a credit for any quantity price reduction earned. 

 ARTICLE VIII – WARRANTIES – REPLACEMENT OF DEFECTIVE INTER-VIAL 
  

	8.1	DUOJECT represents and warrants that all RAAs to be supplied hereunder shall be manufactured and supplied (i) in accordance with the Specifications and all
Applicable Laws, (ii) using no less than industry standard quality control procedures and reasonable care; and (iii) free from defects in material and workmanship. 

 

	8.2	Except for bodily injury, violation of confidentiality obligations, a Failure to Supply, and indemnity obligations, under no circumstances shall either Party be
liable for special, indirect or consequential damages payable to the other Party. 

  

	8.3	DUOJECT represents and warrants that it has current compliance with and will at all times during the term comply with all licenses, permits and approvals of any
relevant governmental or local authorities, as may be required to manufacture and supply the RAA to REVANCE pursuant to the terms and conditions of this Agreement and that DUOJECT has not received any notice of adverse findings from any regulatory
authority with respect to the facilities where the RAA shall be manufactured, packaged and/or stored, which would prevent DUOJECT to perform its obligations hereunder. 

 

	8.4	 DUOJECT represents that it knows of no patent infringement of the RAA, actual or threatened, and knows of no third party patents or other
intellectual property rights which are infringed by the use of the RAA. If REVANCE’s rights with respect to the RAA are 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13 

	 	
enjoined, or if REVANCE has sufficient legal reason to believe that such rights are likely to be enjoined, then DUOJECT may, at its discretion and at DUOJECT’s sole expense, use reasonable
efforts to procure for REVANCE the right to continue exercising such rights, to attempt to replace the RAA with substantially equivalent non-infringing product or to attempt to modify the RAA to become non-infringing, conforming to the requirements
of this Agreement and the Purchase Order. Should DUOJECT be unable either to procure for REVANCE the right to continue to use the RAA or its equivalent or should DUOJECT be unable to modify the RAA to become non-infringing, then at REVANCE’s
election, REVANCE may (but is not obligated to) terminate this Agreement and in such event, REVANCE shall have the option to exercise the License contemplated under Section 6.5. If REVANCE does not exercise such license, then it shall have no
license from DUOJECT to use, distribute and sell the RAA, and in such event, REVANCE shall have the right to return any unsold RAA devices for a full refund and the parties shall be bound by the terms and conditions of Article X hereof.

  

	8.5	DUOJECT undertakes, represents and warrants that it will maintain full traceability of the Lot numbers of all RAM to be supplied hereunder so as to be able to,
and DUOJECT shall, supply REVANCE with any request relating thereto within five (5) Business Days of DUOJECT’s receipt of a written notice. 

  

	8.6	Each Party further represents and warrants to the other that the performance of their respective obligations under this Agreement will not result in a material
violation or breach of any agreement, contract, commitment or obligation to which such Party is a party or by which such Party is bound and will not conflict with or constitute a default under such party’s corporate charter or bylaws, or
violate any Applicable Law; and that such party does not use nor will it use in the future use in any capacity the services of any person debarred under Section (a) or (b) of 21 U.S.C. Section 335a. 

 

	8.7	Subject to Section 8.2, at REVANCE’s option, DUOJECT shall immediately credit free of charge all amounts paid by REVANCE with respect to any RAA that
does not meet the warranties of this Article VIII, or (at REVANCE’s option) shall replace such non-conforming RAA with RAA that meet all such warranties as soon as commercially possible and no later than 90 days of REVANCE’s request, and
shall refund to REVANCE any freight, insurance and transportation charges relating to such return and replacement of any defective or non-conforming RAA. 

  

	8.8	The warranty obligations of DUOJECT under this Article VIII and the sub-sections thereof shall not be construed to include an obligation to provide a warranty
with respect to the following: 

  

	 	(a)	any defect attributable in whole or in part to misuse of the RAAs; 

  

	 	(b)	any damage or defects attributable to the repair or modification of the RAA by any party other than DUOJECT or its authorized manufacturer or supplier.

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 14 

 ARTICLE IX – PRODUCT LIABILITY – INSURANCE 

 

	9.1	Each Party shall notify the other promptly after it learns of information about any incident involving the RAA resulting directly or indirectly in personal
injury, death or damage to property or any side effect associated with the product and/or the RAA. Each of DUOJECT and REVANCE shall cooperate with the other in any reasonable investigation it wishes to make regarding such incident or side effect
and shall make available all statements, reports, tests or other information produced or gathered by it and/or its Affiliates or made available to them by third parties in connection therewith. The furnishing of such information and any
investigation undertaken shall not constitute any assumption of liability with respect to such incidents. 

  

	9.2	Without limiting any other warranties, DUOJECT warrants that all RAAs that would be supplied to REVANCE pursuant to a purchase order will conform to the
Specifications. DUOJECT will convey title thereto free of all liens, claims, encumbrances, or the like, of any kind whatsoever. The warranties In article VIII and IX, and Section 3.3 hereof are the only warranties applicable under this
Agreement All other warranties whether expressed or implied including but not limited to any and all implied warranties of merchantability and fitness for a particular purpose are disclaimed. 

 

	9.3	Subject to Section 8.2 and subject to the conditions set forth in Section 9.5 and the next sentence, provided that the RAA have been manufactured and
supplied according to the Specifications, REVANCE agrees to indemnify and hold DUOJECT harmless from and against any claim, liability, damage or expense (including without limitation, attorneys’ fees) which may be sustained or suffered by
DUOJECT arising in connection with a third party claim resulting from the use of the RAA in the Field (by or through REVANCE or its customers). Notwithstanding the foregoing, REVANCE shall have no obligation to indemnify and hold harmless DUOJECT to
the extent that any injury or loss is the result of a) negligence or misconduct on the part of DUOJECT; b) failure by DUOJECT to comply with applicable laws or regulations; c) failure by DUOJECT to comply with the Specifications or other terms of
this Agreement, or d) any matter for which DUOJECT is responsible for indemnifying REVANCE under this Agreement. 

  

	9.4	DUOJECT agrees to indemnify and hold REVANCE harmless from and against any claim, liability, damage, or expense (including, without limitation, attorneys’
fees) which may be sustained or suffered by REVANCE to the extent that such claim arises in connection with or is the result of (a) the RAA not being manufactured and supplied according to the Specifications or Applicable Laws,
(b) DUOJECT’s negligence, misconduct or breach of any representation, warranty, or covenant hereunder, or (c) the infringement or violation by the RAA (or the manufacture, use or sale thereof) of the intellectual property rights of
any third party. For clarity, the indemnity obligations of DUOJECT shall not apply (as it concerns an infringement issue) if DUOJECT is able to procure for REVANCE the right to continue to exercise its rights and shall also not apply to any
consequential damages of REVANCE in connection with any such claim, but only amounts payable to a third party claimant in connection with indemnified such claim and the defense or settlement thereof. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 15 

	9.5	If any claim arises against a Party (the “Indemnitee’) for which the Indemnitee may seek indemnification from the other Party in accordance with this
Article IX (the “Indemnitor”), the Indemnitee shall promptly notify in writing the Indemnitor of the nature and basis of such claim, and the amount thereof, to the extent known. The Indemnitor shall have the option to assume at its expense
the sole control of the defense of any such claim. The Indemnitor shall thereafter keep the Indemnitee fully informed of the development of such claim and shall not make any settlement thereof without the prior written consent of the Indemnitee,
which shall not be unreasonably withheld. If the Indemnitor does not elect to assume the defense of such claim within a reasonable period following Indemnitee’s notification of such claim, then Indemnitee shall be free to litigate, settle or
otherwise assume the defense of such claim without prejudice to the obligation of Indemnitor to indemnify Indemnitee pursuant to the provisions of this Article IX. 

 

	9.6	Each Party warrants to the other that it is adequately insured and covenants that at all times during the Term of this Agreement it will maintain a comprehensive
general liability insurance for sufficient and adequate protection against the risks associated with ongoing business in amounts customary in its industry for similar services and products. 

ARTICLE X – TERM AND TERMINATION 
  

	10.1	This AGREEMENT shall start on the Effective Date and shall last for a period ending ten (10) years thereafter, or, if later, upon Patent Expiration, unless
earlier terminated as provided for in Article 3.1 and in this Article X. Thereafter, REVANCE shall have the option to renew this Agreement for additional consecutive terms of five (5) years each by providing DUOJECT written notice of its
election within thirty (30) days after the expiration of the then-current term (provided that DUOJECT shall provide REVANCE notice of Patent Expiration to enable its election). The initial term of this Agreement and any renewal terms shall be
collectively referenced herein as the “Term” of this Agreement 

  

	10.2	This Agreement may be terminated by either Party upon written notice if the other Party fails to perform any of its duties or responsibilities or breaches any of
its obligations hereunder, and the Party in breach has not remedied such failure within ninety (90) days from the receipt of notice of such failure from the other Party, subject to 12.1; provided that if either Party disputes any allegation of
breach, the cure period will only commence upon resolution of such dispute in the other Party’s favor (in accordance with Article XI), and both Parties shall be bound to perform their respective obligations hereunder pending such resolution.

  

	10.3	 This Agreement may also be terminated immediately by either Party if the other Party: (i) admits in writing its inability to pay its debts
generally as they become due, (ii) files a petition or has a petition filed against it in bankruptcy or takes any similar action under bankruptcy or insolvency law, rule, regulation or statute that is not dismissed within 120 days thereafter,
(iii) makes a general assignment for the benefit of its creditors, (iv) voluntarily commences a proceeding for the appointment of a receiver, trustee, liquidator or conservator of itself or of the whole or any substantial part of its
property, or 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 16 

 
(v) files a petition seeking reorganization, imposition, liquidation, dissolution or similar arrangement under bankruptcy law or any other applicable law, rule, regulation or statute of any other
jurisdiction. Each Party agrees to promptly notify the other Party of the occurrence of any of these events. 
  

	10.4	Should DUOJECT fail to provide REVANCE with the requirements defined under Article 3.3, and should such failure be confirmed in accordance with Article XI (if
disputed), REVANCE may terminate this Agreement upon written notice to DUOJECT. 

  

	10.5	Upon termination of this Agreement by DUOJECT pursuant to Section 10.2, all outstanding purchase orders placed by REVANCE shall become automatically null
and void. Upon termination of this Agreement by REVANCE pursuant to Section 10.2, REVANCE shall have the option to cancel any outstanding purchase orders or require performance by DUOJECT thereunder. REVANCE shall be obligated to pay DUOJECT
the price for RAA that have been purchased against such outstanding purchase orders unless there is or was a Material Breach by DUOJECT. 

  

	10.6	Upon termination or expiration of this Agreement, both Parties shall promptly return to the other Party all documents or media incorporating confidential
Information received the one from the other (and all copies and extracts thereof). 

  

	10.7	Termination or expiration of this Agreement for any reason shall not release the Parties from their obligations under Articles VIII or IX in their entirety and
section 12.8 which shall survive such termination or expiration. Sections 2.3, 3.3, 6.4, 6.5, 6.6, 7.3, 10.5, 10.6, 10.7, and Articles XI and XII shall also survive any expiration or termination of this Agreement. Neither party shall incur any
liability whatsoever for any damages, loss or expenses of any kind suffered or incurred by the other (or for any compensation to the other) arising from or incident to any termination of this Agreement by such party which complies with the terms of
the Agreement whether or not such party is aware of any such damages, loss, or expenses. 

  

	10.8	 Notwithstanding the provisions of section 3.1 (i) hereof and in addition thereto, this Agreement may be terminated by REVANCE upon 180 days
written notice to DUOJECT at any time following completion of the 4th anniversary of the Election Date, in which event and in addition to the preceding sections of this Article X, REVANCE shall cease and desist from the sale, manufacture, distribution or the commercial or
non-commercial exploitation of the RAA. 

 ARTICLE XI – DISPUTES 

 

	11.1	Any disputes, controversy or claim arising out of or relating to this Agreement or the breach thereof shall be finally settled by arbitration administered by the
American Arbitration Association (“AAA”) in accordance with its rules and judgment on the award rendered by the Arbitrator may be entered in any court having jurisdiction thereof. 

 

	11.2	The number of arbitrators shall be one and the place of arbitration shall be New York City, New York. The substantive law applicable to the dispute shall be that
of the State of New York and of the USA. The language of the arbitration shall be English. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 17 

 ARTICLE XII – GENERAL PROVISIONS 

 

	12.1	Performance under this Agreement shall be excused to the extent and for so long as such performance is impaired, prevented or delayed by an Act of God, such as
war, riot, insurrection, civil commotion, sabotage, fire, flood, earthquake, explosions that damage plants or facilities, acts of governmental authorities or any other cause unavoidable, unforeseeable and beyond the control of either Party
(“Force Majeure”), provided that the Party availing itself of such excuse shall at all times exert its reasonable efforts to remove or avoid such cause and shall have resumed or completed its required performance promptly after such
cause ceased to hinder or delay full performance hereunder. For clarity, any supply failure that lasts more than ninety (90) days due to Force Majeure events shall still be a Failure to Supply. The affected party shall give prompt notice to the
other party of such cause, and shall take promptly whatever reasonable steps are necessary to relieve the effect of such cause. If DUOJECT becomes subject to an event of Force Majeure which interferes with production of the RAA at DUOJECT’s
manufacturing facilities, DUOJECT shall cooperate and assist REVANCE with the transfer of production (including, without limitation, providing the Transition Information) and the parties shall mutually agree on and implement the agreed-upon action
plan to transfer production of the RAA to another manufacturer designated by REVANCE. 

  

	12.2	This Agreement shall inure to and be binding upon the Parties, their successors and permitted assigns. Either Party may, without consent, assign this Agreement
or the rights granted hereunder in whole or in part to an Affiliate upon written notice to the other Party. Assignment to a third party (other than an Affiliate) may be effected only with the prior written consent of the other Party, which will not
be unreasonably conditioned, withheld or delayed; except that, without consent, either Party may assign its rights and obligations hereunder to any successor to all or substantially all of its business that concerns this Agreement (whether by sale
of stock or assets, merger, consolidation or otherwise). Any assignment by a Party of part or all of this Agreement shall not increase the other Party’s obligations or otherwise modify its rights hereunder. 

 

	12.3	Notwithstanding the above, REVANCE agrees that subcontractors of DUOJECT more particularly, and without limitation, Kamek Inc. (“Kamek”) shall
remain primarily and fully under DUOJECT responsibility for the performance of DUOJECT’s obligations under the terms of this Agreement, and DUOJECT shall remain jointly and severally liable for their acts and omissions in connection with the
subject matter of this Agreement. REVANCE acknowledges that DUOJECT will be subcontracting a material portion of its obligations under this Agreement, in particular, with Kamek. All other subcontractors with which DUOJECT intends to deal shall be
subject to REVANCE’s prior written approval which approval shall not unreasonably be withheld. 

  

	12.4	Nothing in this Agreement shall create, or be deemed to imply the creation of, any partnership, joint venture, or principal and agent relationship between
REVANCE and DUOJECT, it being understood that the Parties have entered and shall perform this Agreement as independent contractors. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 18 

	12.5	Any notice, report or other written communication required or permitted to be made or given hereunder may be made or given by either Party to the other by
personal in-hand delivery, by facsimile (fax) or electronic-mail, by first class mail, postage pre-paid, or by air courier, to the mailing address or FAX number or electronic-mail address set forth below: 

 

					
	If to DUOJECT:	 	DUOJECT MEDICAL SYSTEMS INC.
		 	50 de Gaspé Street, Complex B-5
		 	Bromont, Quebec, Canada
		 	J2L 2N8
		 	Attention:	 	Daniel MacDonald, VP, Engineering Services
		 	Fax:	 	(450) 534-3700
		 	E-mail:	 	dmacdonald@duoject.com
		
	With a copy to:	 	JOEL A. PINSKY
		 	2 Place Alexis Nihon, Suite 1000
		 	Montreal, Quebec, Canada
		 	H3Z 3C1
		 	Fax:	 	(514) 933-0810
		 	E-mail:	 	jpinsky@pzssa.ca
		
	If to REVANCE:	 	REVANCE THERAPEUTICS, INC.
		 	7555 Gateway Blvd.
		 	Newark, California, U.S.A.
		 	94560
		 	Attention:	 	Daniel Browne and Curtis Ruegg
		 	Fax:	 	(510) 742-3401
		 	E-mail:	 	dbrowne@revance.com; cruegg@revance.com

 Or to such other address or fax or electronic-mail as either Party shall designate by written notice,
similarly given, to the other Party. Notices or written communications shall be deemed to have been sufficiently made or given (i) if by personal in-hand delivery, or by fax or electronic-mail with confirmed transmissions, when performed,
(ii) if mailed, five (5) days after being deposited in the mail, registered postage prepaid; or (iii) if by air courier, three (3) days after delivery to the air courier company. 

 

	12.6	The terms and provisions of this Agreement, constitute the entire agreement between the PARTIES, hereto relating to the subject matter hereof and supersede all
prior oral or written agreements, communications or understandings with respect to this subject. Except, however, for any confidentiality agreements entered into by the Parties relating however to the matter hereof which shall remain valid
notwithstanding this Agreement and to the extent they are not modified by this Agreement. Any conflicting or inconsistent terms contained in any invoice or order confirmation shall be deemed null and void. Any amendment or modification of this
Agreement shall only be effective when agreed upon by the Parties, in writing specifically referring to this Agreement and executed by duly authorized representatives of each Party. Failure by a Party to exercise or enforce any right hereunder shall
not be deemed a waiver of such right or any other right, nor operate to bar the exercise or enforcement of such right at any time thereafter. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 19 

	12.7	Neither REVANCE nor DUOJECT will originate any publicity, news release, or other public announcement or comment, written or oral, relating to this Agreement,
whether to the press, or otherwise, without the advance written consent of the other Party (which consent shall not be unreasonably withheld), except for any announcement which is required by law. A Party giving an announcement that is required by
law will give the other Party an opportunity to review the form and content of such announcement and comment upon it to the extent practical. 

  

	12.8	The Parties hereto acknowledge that certain information exchanged between them under this Agreement is proprietary and confidential to the disclosing Party.
Confidential Information means all information disclosed hereunder, whether in writing or orally, which is identified as being confidential or which would be apparent to a reasonable person familiar with the pharmaceutical industry to be information
of a confidential or proprietary nature. Each Party agrees not to use (except to perform its obligations hereunder) or disclose any Confidential Information to any third party (other than employees or agents of such Party or to its Affiliates of
stockholder who need to know such Confidential Information to permit the performance of this Agreement and who are bound by a comparable obligation of confidentiality) without the express written consent of the disclosing Party, unless such
materials: 

  

	 	(a)	were known to the Party receiving the Confidential Information prior to the disclosure as evidenced by that PARTY’S written records; or 

 

	 	(b)	become generally available to the public through no fault of the receiving Party; or 

 

	 	(c)	are received by a Party in good faith from a third party, not in breach of an obligation of confidentiality; or 

 

	 	(d)	are independently developed by the Party as evidenced by dated written documentation receiving Confidential Information without use of such Confidential Information of
the other party. 

 Notwithstanding the above, nothing contained in this Agreement shall preclude either Party from
utilizing Confidential Information as may be necessary in obtaining governmental regulatory approvals, exercising their respective rights and licenses with respect to the RAA pursuant to the terms and conditions of this Agreement, or complying with
Applicable Laws or court orders. These obligations of non-use and confidentiality shall be effective during the term of this Agreement and shall also survive for ten (10) years following the termination or expiration of this Agreement. Upon the
termination of this Agreement, all Confidential Information received by the disclosing party hereunder (and all copies and extracts thereof) shall be returned to the disclosing Party, except for a single copy to be kept in the receiving Party’s
confidential file solely for the purposes of determining compliance with its obligations of confidentiality hereunder. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 20 

	12.9	This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. 

  

	12.10	This Agreement is negotiated and drafted in the English language and only the English text will be binding upon the Parties. It is further agreed upon that any
and all reports, notes or other documents that are to be provided hereunder by one Party to the other Party, will be provided in the English language. 

  

	12.11	The Parties agree that this Agreement shall be treated as Confidential Information, but each party may disclose this Agreement as required by law and in
connection with acquisition and financing activities. 

 ARTICLE XIII – RIGHT OF FIRST REFUSAL

  

	13.1	In the event that DUOJECT shall receive from a third party at any time during the Term an offer to license the RAA for a use other than in the Field at a
specified price, terms and conditions (hereinafter referred to as the “Bona Fide Offer”) whether such price, terms and conditions be fixed by DUOJECT or the third party, and DUOJECT shall decide to license the RAA for such use and for such
price, DUOJECT shall promptly give to REVANCE notice of any such offer received from a third party and of DUOJECT’s willingness to license the RAA outside the Field for the price and for the use and for the terms and conditions offered. REVANCE
shall have the first refusal and privilege (which will hereafter be referred to as an “Option”) of licensing the RAA outside the Field at such price, terms and conditions and in such area of use as was specified in the Bona Fide Offer.

  

	13.2	REVANCE shall be obliged to exercise or decline the Option within ten (10) business days after REVANCE receives notice from DUOJECT of the Bona Fide Offer
by REVANCE notifying DUOJECT that REVANCE will license (or declines to license) the RAA for the price, terms and amounts and in and for the use specified in the Bona Fide Offer. In the event that REVANCE shall not give DUOJECT within the said ten
(10) business day period notice of its election to license the RAA for the uses and for the price, terms and conditions specified in the Bona Fide Offer, DUOJECT may thereafter license the RAA outside the Field to the party making the offer
subject, however, to the terms and conditions of this Agreement. If for any reason the RAA are not licensed to such third party upon the specified use, price, terms and conditions, notice of any subsequent Bona Fide Offer to license the RAA outside
the Field acceptable to DUOJECT shall be given to REVANCE upon the same terms and conditions for acceptance or rejection as herein above provided. 

 The following Annexes hereto form an integral part of this Agreement: 
  

	 	•	 	 Annex “A”: PRODUCT DESIGN SPECIFICATIONS 

  

	 	•	 	 Annex “B”: TIMELINE AND PROJECT PLAN 

  

	 	•	 	 Annex “C”: DEVELOPMENT MILESTONES/PAYMENTS 

  

	 	•	 	 Annex “D”: PRICE SCHEDULE 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 21 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed and delivered in duplicate
by their duly authorized representatives with legal and binding effect as of the Effective Date 
  
  

					
	DUOJECT MEDICAL SYSTEMS INC.	 		 	REVANCE PHARMACEUTICALS, INC.
			
	         /s/ David Reynolds
	 		 	         /s/ Curtis Ruegg

	PER: DAVID REYNOLDS, President	 		 	PER: CURTIS RUEGG, EVP R&D
			
	I have authority to bind the Company	 		 	I have authority to bind the Company

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 22 

 ANNEX “A” 

PRODUCT DESIGN SPECIFICATIONS 
 [***] 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 23 

 ANNEX “B” 

TIMELINE AND PROJECT PLAN 

[***] 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 24 

 ANNEX “C” 

DEVELOPMENT MILESTONES/PAYMENTS 
 Development activities 
 DUOJECT will perform design work to meet the proprietary status of
the RAA for REVANCE according to the specifications contained in the PDS document. 
 Development costs below (Customization Schedule) include
engineering work performed on the RAA in order to customize DUOJECT’s existing technology to comply with REVANCE’s requirements. 

Results of focus studies conducted by REVANCE chosen physicians as well as upcoming FDA feedback may generate additional design work on the RAA. This
information, once shared with DUOJECT, will be converted into Design Input Requirements and incorporated in the PDS prior to design freeze and PDS final approval. Below Customization Schedule costs therefore also include estimates for additional
engineering design work to come and are subject to change once design is frozen and final PDS is approved. 
 Only once new design inputs are
received from REVANCE and PDS is approved will tooling modification costs be available to share with REVANCE. 
 Tooling and assembly costs
listed below are for large production volumes of the RAA that will most likely not be required until 2012, once FDA approval is received by REVANCE. Tooling costs for all plastic components are listed for [***] production molds. Capital investments
for semi-automatic and upgrade to fully automated assembly are budgetary as final quotations have yet to arrive from machinery vendors. Firmer numbers will be provided to REVANCE as soon as available. 

Note that Engineering or Tooling costs already paid by REVANCE to DUOJECT are not included in list below. 

Relying upon Revance’s e-mail to Duoject of February 1st, 2010 by which ReVance agreed to reimburse Duoject 50% of the price of the RAA tooling
within a short delay following the receipt by ReVance of a regulatory notice permitting the marketing of the RAA, Duoject agrees to purchase a set of 4-cavity cold runner production tools, as described in Milestone Payments below, for the injection
molding of the Duoject Components of the ReVance RAA required for CT3 trials in Q3 2010. 
 Milestone Payments 

[***] 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 25 

 ANNEX “D” 

PRICE SCHEDULE 
 DUOJECT
will apply the following incremental prices per RAA for each 12 month period starting with the first delivery to REVANCE. 
 [***] 

Pricing for RAA is ex works and includes molded components and automated assembly (production RAA). Prices also include packaging in PE double-bags as
well as gamma sterilization on route to contract filler/final assembler. 
 Suggested shipment scenario for RAAs: packaged [***] per box, [***]
boxes per pallet. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 26 

 ANNEX “E” 

Duoject Engineering Services Rates – 2010 
 [***] 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 27EX-10.18

 Exhibit 10.18 
 [ ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the
Securities Act of 1933, as amended. 
 DEVELOPMENT AND SUPPLY AGREEMENT 

THIS DEVELOPMENT AND SUPPLY AGREEMENT (this
“Agreement”) is made as of this 11 day of December, 2009 (the “Effective Date”) by and between Revance Therapeutics, Inc., having a principal place of business at 7555 Gateway Boulevard, Newark, CA
94560 (“Revance”) and Hospira Worldwide, Inc., having a principal place of business at 275 North Field Drive, Lake Forest, Illinois, 60045, (U.S.A.) (“Hospira”). 

WITNESSETH: 
 WHEREAS, Revance owns global rights to the compound RT001, a topical drug, and wishes to develop and market RT001 in combination with a poloxamer cartridge as the
diluent; 
 WHEREAS, Revance and Hospira desire that Hospira assist Revance in the
development and commercialization of the poloxamer cartridge; and 
 WHEREAS, after Revance
has received an approved new drug application from relevant Regulatory Authorities, the parties desire that Hospira manufacture and sell to Revance its full requirements of the poloxamer cartridge, subject to the terms herein. 

NOW, THEREFORE, in consideration of the premises and the mutual promises and
agreements contained herein, Revance and Hospira agree as follows: 
 ARTICLE 1. DEFINITIONS 

The following words and phrases when used herein with capital letters shall have the meanings set forth or referenced below: 

1.1 “Affiliate” means, with respect to a party, any corporation, company, partnership, joint venture and/or firm
which controls, is controlled by or is under common control with such party. As used in this Agreement, “control” means: (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent
(50%) of the stock or shares having the right to vote for the election of directors; and (b) in the case of non-corporate entities, the direct or indirect power to manage, direct or cause the direction of the management and policies of the
non-corporate entity or the power to elect at least fifty percent (50%) of the members of the governing body of such non-corporate entity. 
 1.2 “Applicable Law” shall mean all laws applicable to the Manufacture, processing, marketing, and distribution of the Product, including, without limitation, the U.S. Federal
Food, Drug, and Cosmetic Act, as amended, and the regulations promulgated thereunder, including all applicable cGMP; and all other corresponding laws, ordinances, rules and regulations of any other applicable jurisdiction in the Territory.

 1.3 “cGMP” shall mean those principles and guidelines of good manufacturing practices as set forth in
21 C.F.R. Parts 210 and Part 211; the ICH Guideline on Good Manufacturing Practice for Active Pharmaceutical Ingredients (ICH Q7A) and the corresponding requirements of each other applicable jurisdiction. 

  
 1. 

 1.4 “Confidential Information” shall mean all information disclosed
hereunder in writing and identified as being confidential or, if disclosed orally, visually or through some other media, is identified as confidential at the time of disclosure, except any portion thereof which: 

(a) is known to the recipient at the time of the disclosure, without restriction, as evidenced by its written records or other competent
evidence; 
 (b) is disclosed to the recipient by a third person lawfully in possession of such information and not under an
obligation of nondisclosure; 
 (c) is or becomes patented, published or otherwise part of the general public domain through no
fault of the recipient; 
 (d) is developed by or for the recipient independently of Confidential Information disclosed
hereunder as evidenced by the recipient’s written records or other competent evidence; or 
 (e) is required by law to be
disclosed by the recipient, but only to the extent required and only for that limited purpose, and provided that the recipient gives the other party hereto prompt notice of such legal requirement such that such other party shall have the opportunity
to apply for confidential treatment of such Confidential Information. 
 1.5 “Commercial Year” shall
mean a period of twelve (12) consecutive months which, for the first Commercial Year of this Agreement, shall commence on the first day of the month after the month of Revance’s first bona fide sale of the Product to a non-Affiliate
customer after the Product has received a regulatory approval from any Regulatory Authority, and each Commercial Year thereafter shall consist of twelve (12) consecutive months following the end of the preceding Commercial Year. 

1.6 “Components” means the excipients and all components or component parts of the Product including labeling,
packaging, ancillary goods, shipping materials and other items to be supplied by Hospira to manufacture the Product in accordance with the Product Specifications. 
 1.7 “FDA” means the United States Food and Drug Administration or any successor entity. 
 1.8 “Product” shall mean a poloxamer cartridge meeting the Product Specifications. 
 1.9 “Product Specifications” shall mean those product, labeling and performance specifications for the Product, including Product formulae, labeling, and materials required for the
manufacture of the Product that is to be purchased and supplied under this Agreement, as such are set forth on Exhibit 1.9, which specifications may be amended from time to time by the written agreement of the parties. 

1.10 “Regulatory Authority” shall mean any United States federal, state or local or other regulatory agency,
department, bureau or other governmental entity in the Territory, including the FDA, which is responsible for issuing approvals, licenses, registrations or authorizations necessary for the manufacture, use, storage, import, transport, sale and use
of the Product in any applicable regulatory jurisdiction in the Territory. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2. 

 1.11 “Specially Regulated Waste” shall mean any hazardous waste,
toxic waste, medical waste, nuclear waste, mixed waste, or other waste materials or by-products, including waste water, which may be subject to or require special handling, treatment, storage, or disposal under any federal, state or local laws or
regulations intended to address such types of waste materials that arise from the manufacture of the Product. 
 1.12
“Territory” shall mean the United States of America plus any other countries mutually agreed to in writing by the Parties. 
 1.13 “Third Party” shall mean a party other than Hospira or Revance and their respective Affiliates. 
 1.14 “Waste” shall mean all rejects, improper goods, garbage, refuse, remainder, residue, waste water or other discarded material, including solid, liquid, semisolid, or contained
gaseous material that arises from the manufacture of the Product, including but not limited to, rejected, excess or unsuitable materials, API and Products. The term Waste shall not include any Specially Regulated Waste. 

ARTICLE 2. PRODUCT DEVELOPMENT PROJECT 

2.1 General. Promptly following the Effective Date, the parties shall undertake a product development project
(“Project”) consisting of the development activities set forth on Exhibit 2.1 (“Statement of Work”). Under the Project, Hospira shall with Revance’s cooperation develop the Product and use
commercially reasonable efforts to assist Revance to obtain the required NDA. Hospira then shall manufacture and deliver Product to Revance for sale by Revance as a human pharmaceutical product. 

2.2 Commercially Reasonable Efforts. Each party shall use all commercially reasonable efforts successfully to complete the
Project. However, the parties understand and agree that neither of them can guarantee that the Project will be successful, nor warrant that a marketable product will result from the Project. 

2.3 Development Fee. Revance shall pay to Hospira a non-refundable development fee in the amount of [***] (the
“Development Fee”) for its work under the Project in accordance with the payment schedule set forth in Exhibit 2.3. In the event that either of the parties terminates this Agreement prior to its term in accordance with
Article 9, Hospira will deliver all results (including Project Inventions) of the Project to Revance and Revance will pay to Hospira that portion of the Development Fee that represents: (a) the development work Hospira has properly
completed and for which payment has not yet been received; and (b) on a pro rata basis, all development work that Hospira has properly undertaken but not yet completed as of the date of notice of termination. In addition, Revance shall
reimburse Hospira for all of its pre-approved out-of-pocket costs related to any non-cancelable commitments for raw materials, components and services that Hospira has undertaken as part the Project. Notwithstanding any language to the contrary, if
Revance has paid for any of the development activities set forth on Exhibit 2.1 in accordance with the letter agreement between the parties dated October 15, 2009 (“Letter Agreement”), Revance shall not be obligated to
pay Hospira for such development activities under this Agreement. As of the Effective Date Revance has paid [***] under the Letter Agreement (in accordance with Exhibit 23(a) of this Agreement). 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 3. 

 2.4 Development Stability Studies. Hospira will prepare stability batches of
the Product and perform stability studies as reasonably directed by Revance (“Stability Work”) separate and apart from the Project for a separate fee of [***]. 

2.5 Changes in Project Scope. If Revance requests changes in the Project, Product or the Product Specifications, or if
reasonably unforeseeable technical difficulties beyond the control of Hospira require that Hospira perform either additional work or repeat work, and such additional work or repeat work is not required due to Hospira’s fault or negligence,
Hospira shall provide Revance with cost estimates for such work. If Revance approves such costs in writing, Hospira shall perform such work and Revance shall pay Hospira’s estimated costs for such work within [***] of completion of such work.
Reimbursement for such additional work or repeat work shall be at the rate of [***]; plus pre-approved out-of-pocket costs for reasonable travel and sustenance, materials and supplies. 

2.6 Technical Contact. Each Party will appoint a “Technical Contact” having primary responsibility for day-to-day
interactions with the other Party for the activities under the Development Project. Any change to a Technical Contact will be identified in writing to the other Party. Each Party will use reasonable efforts to provide the other Party with at least
thirty (30) days prior written notice of any change in that Party’s Technical Contact. All communications between Hospira and Revance regarding the conduct of the activities under the Development Project will be addressed to the
Party’s relevant Technical Contact. 
 2.7 Development Supplies. Based on Revance’s final Product
formulations, concentration and fill volume and the Product Specifications, Hospira will manufacture the Products in engineering runs and for process validation purposes (“Development Supplies”) at the prices set forth in
Exhibit 2.7. The parties acknowledge that Development Supplies include material utilized for the development purposes such as clinical trial product and stability testing material, but do not include materials intended for commercial
sale in the market. Revance shall issue a purchase order for any such Development Supplies at least [***] before the requested delivery date. 
 ARTICLE 3. REVANCE’S REGULATORY SUBMISSIONS 
 3.1 Regulatory Review. 
 (a) Per Exhibit 2.1, Hospira
shall review and provide feedback on those portions of Revance’s proposed regulatory submissions relating to Hospira’s manufacturing or packaging procedures before the submissions are filed with relevant Regulatory Authorities. Hospira
shall complete its review of any English-language submissions within [***] after receipt. If the Territory is expanded pursuant to Section 1.12 to include other countries then the parties will agree on the time required for
Hospira’s review of submissions in other than English language without translation, which will extend Hospira’s review period for the purpose of providing a reasonable period for document translation. 

(b) Hospira shall consult with and advise Revance in responding to questions or concerns from United States Regulatory Authorities
regarding Revance’s submission(s) for the Products, provided that Revance shall have the final control over such submissions. If the Territory is expanded pursuant to Section 1.12 to include other countries then Hospira shall
provide Revance with cost estimates for any required additional review and consultation as it 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 4. 

 
concerns filings outside the United States. If Revance approves such costs in writing, Revance shall reimburse Hospira for such additional activities at the rate of [***]. Revance shall be the
sole owner of any regulatory submission filed pursuant to this Agreement. Revance shall provide to Hospira for its files a final copy of the CMC section of any such regulatory submission(s). All of Hospira’s obligations under this
Section 3.1 shall be performed using appropriately skilled personnel with relevant experience. 
 3.2 Access
to Drug Master Files. Hospira shall provide Revance access to, and grant Revance reference rights to, all Drug Master Files (“DMFs”) necessary to support Revance’s applications for regulatory approval of the
Product. To affect this, Hospira shall execute certain documentation (“Letters of Authorization”) which shall be delivered to the appropriate Regulatory Authorities permitting such Regulatory Authorities to consult
Hospira’s DMFs in their review of Revance’s Product regulatory submissions. Hospira shall send copies of such Authorization Letters to Revance. Hospira shall update its DMFs annually and shall inform Revance reasonably in advance of any
modifications thereto in order to permit Revance to amend or supplement any affected regulatory submissions and filings for Product; provided that any such change that would impact the Product Specifications (or Hospira’s ability to supply
Product in accordance therewith) shall require Revance’s prior written approval. 
 3.3 User Fees. Revance
shall pay any Regulatory Authority user fees which may become payable for the Product. 
 ARTICLE 4.
MANUFACTURE AND SUPPLY OF PRODUCT 
 4.1
Purchase and Sale of Product. Pursuant to the terms and conditions of this Agreement and for the term of this Agreement, (i) Hospira shall manufacture, sell and deliver the Product to Revance, and (ii) Revance shall purchase
and take delivery of its total requirements of poloxamer cartridges for the Territory exclusively from Hospira. [***]. 
 4.2
Manufacturing Standards. Hospira shall manufacture Product in accordance with the Product Specifications and Applicable Law. The parties may amend the Product Specifications from time to time by written agreement without amending this
Agreement. 
 4.3 Government Approvals. Hospira agrees to manufacture and supply those quantities of Products
requested in firm purchase orders by Revance that are necessary to validate Hospira’s manufacturing facilities, obtain regulatory approval(s) and build Revance’s inventory in anticipation of commercial launch of the Products and Revance
shall be required to pay for such Products irrespective of whether the Products ultimately receive all necessary Regulatory Authorities’ approvals. 
 4.4 Dedicated Equipment; Costs. If specialized or dedicated equipment is required to manufacture Product for Revance, Hospira shall pay the cost of such equipment, subject to Revance’s
prior approval of such costs, which approval shall not be unreasonably withheld. Hospira shall advise Revance of specialized equipment required and the estimated costs associated with the purchase, installation and validation of such equipment.
After Revance approves such costs, Hospira shall install and validate the equipment and bill Revance for the associated pre-approved costs. Revance shall make such payment to Hospira no later than [***] after Revance receives an invoice from
Hospira. Title to the equipment shall be in Revance’s name and shall be maintained free of any liens, claims, encumbrances, or the like. If Hospira 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5. 

 
wishes to use the specialized or dedicated equipment for manufacture of a product other than Product for Revance, Hospira and Revance shall meet and discuss the technical and practical
ramifications of such use and appropriate compensation to Revance. Any such use shall be subject to Revance’s prior written approval. 
 4.5 Components. Hospira shall be responsible for the supplies of the Components required for the Manufacture of the Product. Hospira will source all of the Components from suppliers that
have been approved and qualified by Hospira in accordance with Hospira’s internal vendor qualification and approval processes, and to the extent a specific vendor of a Component is listed in the Product Specifications, Hospira shall only obtain
such Component from such listed vendor. The parties understand and agree that Revance will have reviewed and approved the Components and Component suppliers listed in the Product Specifications. Under no circumstances shall either party have any
liability, nor be deemed to be in breach of this Agreement, if Hospira is unable to supply the Product to Revance due to a failure of such suppliers to provide such Components that have been ordered by Hospira; provided such failure is not due to
the fault or negligence of Hospira (e.g., Hospira’ s failure to make timely orders from such Component suppliers). 
 4.6
Product Labeling. 
 (a) Hospira shall label the Product in accordance with the Product Specifications using
content provided by Revance. Revance shall control the content and type of all labeling and packaging (and any changes or supplements thereto) for the Product and shall have the responsibility, at Revance’s expense, for: (i) ensuring such
content is compliant with regulatory approvals and all Applicable Law; and (ii) any changes or supplements to such content, including the expense of securing any approvals required any applicable Regulatory Authority for any such changes or
supplements. Hospira shall be responsible for obtaining such labels (and any changes or supplements thereto) in accordance with the content specified by Revance. 
 (b) Any changes to the labeling and packaging shall be communicated to Hospira in writing at least [***] prior to the desired implementation date together with the required documentation specifying the
content to be included in the labeling and packaging, including all necessary photo-ready art (or its substantial equivalent). Revance shall reimburse Hospira for Hospira’s actual pre-approved costs of making any changes under this
Section 4.6(b) and for the cost of any labeling that Hospira is unable to use due to such changes. 
 4.7 Off-Site
Waste. If necessary, Hospira shall hire, direct and pay all costs for a waste contractor to remove all Waste from Hospira’s manufacturing facility for Product consistent with the Product’s Material Safety Data Sheets
(“MSDS”). The pre-approved costs associated with the removal of Specially Regulated Waste shall be borne by Revance. Hospira shall only dispose of Specially Regulated Waste at sites and through waste management vendors that
have been approved in writing by Revance, whose approval shall not be withheld unreasonably. Hospira shall document the destruction of any Specially Regulated Waste in writing and provide copies of such written documentation to an authorized
representative of Revance. Revance maintains the right, but not the obligation, to witness the actual disposal of Specially Regulated Waste. Revance shall, upon request by Hospira, provide the MSDS for the API and the MSDS for the Product to
Hospira. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6. 

 4.8 Delivery. Hospira shall ship the Products to Revance or its designee, EXW
(Incoterms 2000), Hospira’s manufacturing plant at [***], in accordance with the delivery dates set forth in Revance’s Purchase Orders that have been accepted under Section 5.5. Title to and risk of loss over the Products shall
pass to Revance at the time the Product is made available to Revance’s designated carrier at the loading dock of Hospira’s [***] facility. Hospira shall not ship any Product until both Hospira and Revance have released such Product
pursuant to the Product Specifications and the Quality Agreement. Revance will be responsible for procuring Marine insurance in an amount sufficient to cover the value of the contents, for all shipments to Revance or its designee. All freight,
handling, insurance, duties, taxes and shipping expenses after Revance’s designated carrier has accepted the Products at [***] will be borne by Revance. 
 4.9 Price and Payment. 
 (a) Price. Hospira shall
invoice Revance for Product delivered by Hospira at the prices set forth on Exhibit 4.9. Prices are firm through [***]. Beginning [***] and each succeeding [***] during the term of this Agreement, Hospira shall have the right only once
per calendar year to increase the price of the Product. Price increases shall be effective for deliveries following the applicable price increase. Such increases shall not exceed [***]. 

(a) Payment. Hospira shall invoice Revance upon shipment of Product. Revance shall make payment [***] from the date of
receipt of Hospira’s invoice. 
 (b) Taxes. Any federal, state, county or municipal sales or use tax, excise,
customs charges, duties or similar charge, or any other tax assessment (other than that assessed against income), or other governmental fee or charge lawfully assessed or charged on the sale or transportation of Product sold pursuant to this
Agreement, and all government license filing fees and Prescription Drug User (PDUFA) annual establishment fees with respect to all Product (for supply to Revance) shall be paid by Revance. 

(c) Process Rework. Process rework to the extent created as a result of Revance’s changes shall be billed separately
at a reasonable fee mutually agreed upon in writing. 
 (d) Sub-Lots. Should Revance request Hospira to split a
manufacturing lot of Product into several sub-lots during packaging, there will be a split fee of [***] for each sub-lot packaged. 
 (e) Storage Fee. A cold storage fee shall be due and payable to Hospira if Revance stores Product at Hospira’s [***] facility greater than [***] after Revance receives written notice of
the applicable Product’s release by Hospira. The fee shall be [***]. Revance will use its commercially reasonable efforts to take delivery of all Products from Hospira’s [***] facility no later than thirty (30) days after Revance
receives written notice of the applicable Hospira’s release of the Product. 
 4.10 Inspection; Nonconforming
Shipment. 
 (a) CoA. Hospira will include a Certificate of Analysis with each batch of Products
confirming that the Products have been manufactured in conformity with the Product Specifications and all Applicable Laws. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7. 

 (b) Inspection; Rejection. Revance shall have a period of [***] from the date
of its receipt of a shipment of Product to inspect and reject such shipment for nonconformance with the Product Specifications. If Revance rejects such shipment, it shall promptly so notify Hospira and provide to Hospira samples of such shipment for
testing. If Hospira tests such shipment and determines that it did conform to the Product Specifications, the parties shall submit samples of such shipment to a mutually acceptable independent laboratory for testing. 

(c) Testing. If such independent laboratory determines that the shipment conformed to the Product Specifications, Revance
shall bear all expenses of shipping and the independent laboratory’s testing such shipment samples. If Hospira or such independent laboratory confirms that such shipment did not meet the Product Specifications, Hospira shall replace, at no cost
to Revance, that portion of the Product shipment which does not conform to the Product Specifications as soon as commercially reasonable, and shall bear all expenses of shipping and the independent laboratory’s testing the shipment samples
after Revance’s notification of non-conformity. Revance shall dispose of any nonconforming portion of any shipment as directed by Hospira, at Hospira’s expense. 
 (d) Deemed Acceptance; Latent Defects. Any Product that Revance does not reject pursuant to this Section 4.10 shall be deemed accepted, and all claims with respect to Product not
conforming with Product Specifications shall be deemed waived by Revance, except with respect to latent defects which are not discoverable by the exercise of ordinary diligence and reasonable care, which render the Product not conforming to Product
Specifications and are solely caused by Hospira. The parties shall consult to confirm the cause of the latent defect. If it is confirmed that the cause of the defect is solely attributable to Hospira, then Hospira will replace at no cost to Revance
all such defective Products with Products that meet the Product Specifications as soon as commercially reasonable. 
 ARTICLE
5. ORDERS AND FORECASTS 
 5.1 [***] Product Supply Forecast. For
capacity planning purposes, upon regulatory submission, Revance shall provide Hospira with a written non-binding (other than for the purposes of Section 5.7 for which such forecast shall be deemed binding) forecast of Revance’s
annual requirements of Product for [***]. Thereafter, by [***] of each calendar year Revance shall update such rolling forecast of its requirements of the Product for the period commencing on [***] of the next calendar year. 

5.2 First Firm Order. The parties shall cooperate in estimating and scheduling production for Revance’s first
commercial order approximately [***] in advance of the anticipated date of Product approval by a Regulatory Authority or the desired Product availability date. 
 5.3 Rolling Forecast. Concurrent with the placing of its first commercial order, and on [***] for the first Commercial Year, Revance shall provide to Hospira a good faith, estimated rolling
forecast of the quantity of Products that Revance expects to order for the coming [***] period of time (each, a “Rolling Forecast”). The first [***] of each Rolling Forecast shall be considered a binding commitment upon
Revance to purchase quantities described therein and a binding commitment upon Hospira to produce and deliver such quantities on the delivery dates described therein (“Firm Order Period”). The last [***] of each Rolling
Forecast shall be non-binding upon the parties. After the first Commercial Year, Revance shall provide [***] Rolling Forecast on a [***] constituting the Firm Order Period. [***] of each such Rolling Forecast shall be non-binding upon the parties.

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8. 

 5.4 Purchase Orders. On or before the first day of each calendar month,
Revance shall submit a purchase order (“Purchase Order”) to Hospira. Revance shall submit each Purchase Order to Hospira at least [***] prior to the requested delivery date of the Product. Provided Purchase Orders are placed
in accordance with such time frame and are consistent with the quantities listed in the applicable Firm Order Period of the Rolling Forecast (subject to Section 5.6), Hospira shall meet the delivery dates set forth in each Purchase Orders. Each
Purchase Order shall reference this Agreement and shall be governed exclusively by the terms contained herein. Any terms or conditions contained in a Purchase Order, invoice or order confirmation that are inconsistent or in conflict with this
Agreement shall be deemed not to be a part of such purchase order (except quantities, prices, Products, and delivery location terms). 
 5.5 Firm Order Acceptance. Within [***] after receipt of a Purchase Order issued in accordance with Section 5.4, Hospira shall confirm to Revance its acceptance of the Purchase
Order, delivery date(s), the quantity of Products ordered and the purchase price to be paid by Revance. Hospira may reject, in whole or in part, a Purchase Order only if it calls for the delivery of Products in less than [***] after the Purchase
Order was issued by Revance or it is not consistent with the quantities listed in the applicable Firm Order Period of the Rolling Forecast (subject to Section 5.6). 

5.6 Additional Quantities. Should Revance order additional quantities of Product in excess of [***] over the applicable
Firm Order Period for the first Commercial Year or [***] over the applicable Firm Order Period for subsequent Commercial Years, Hospira shall not be obligated to supply said additional quantities; provided, however, that Hospira shall
supply excess Product within the limits of this sentence and shall use reasonable commercial efforts to produce and deliver to Revance any additional quantities within [***] of issuance of the Firm Order for such additional quantities. 

5.7 Minimum Purchase Requirement. Although Revance covenants to purchase from Hospira its total requirements of poloxamer
cartridges for the Territory, starting [***], Revance further covenants to purchase from Hospira not less than [***] units of Product for the upcoming calendar year [***] (“Minimum Purchase Requirement”). [***] In lieu of
Revance taking delivery of all of the Minimum Purchase Requirement, Revance shall have the option to pay for the shortfall of the Minimum Purchase Requirement at the applicable prices determined in accordance with Section 4.9 and waive
Hospira’s manufacture and delivery obligations for such Product. In the latter event, Hospira shall invoice Revance for the amount payable, and Revance shall pay Hospira within [***] after receipt of Hospira’s invoice. Notwithstanding
anything of the foregoing, all payments by Revance for Products shall count towards the Minimum Purchase Requirement including, without limitation, any payments made in the event of Firm Order cancellation pursuant to Section 5.8(b).
[***]. 
 5.8 Firm Order Changes; Cancellations.  

(a) Changes. If Revance requests that changes be made to any of its Purchase Orders within the Firm Order period, Hospira
shall use commercially reasonable efforts to accommodate such changes within reasonable manufacturing capabilities and efficiencies. If Hospira can accommodate such changes, Hospira shall advise Revance of any costs associated therewith. If

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9. 

 
Revance indicates in writing to Hospira that it should proceed to make the changes at such costs, Revance shall be deemed to have accepted the obligation to pay Hospira for such costs. If Hospira
cannot accommodate such change, Revance shall nonetheless be bound to its original Firm Orders. 
 (b)
Cancellations. If Revance cancels any Purchase Order within the Firm Order Period, Revance will not be relieved of its payment obligation unless Hospira agrees to waive such obligation in writing. If Hospira does not waive such payment
obligation in writing then Revance may, at its option, take delivery of any Products to be manufactured in connection with such Purchase Orders or elect not to have such Product manufactured, in which case Revance will not be relieved of its payment
obligation to Hospira for such Product but Hospira will be relieved of its manufacturing obligations relating to such Product. 

5.9 Shortage of Supply. In the event that Hospira is unable or unwilling to manufacture or supply the Product in accordance
with Revance’s firm Purchase Orders that have been previously accepted by Hospira (“Shortage of Supply”), Hospira shall notify Revance promptly. To the extent the inability is not: (a) caused by an event of force majeure;
(b) attributable to Revance’s breach of its obligations under this Agreement; or (c) attributable to any Component supplier’s acts or omissions, then Hospira shall be solely responsible for undertaking all commercially reasonable
measures to minimize any possible shortage of Product to Revance as a result of its manufacturing or other issues. If Hospira cannot undertake such measures promptly and is unable to supply the Product in accordance with Revance’s firm Purchase
Orders that have been previously accepted by Hospira (“Failure to Supply”), then either party may request that the Technical Contacts convene a meeting to discuss possible remedial action, which at a minimum shall include an equitable
reduction in Revance’s Minimum Purchase Requirements for the applicable Commercial Year and Transfer of Production under Section 11.1(b). 
 ARTICLE 6. QUALITY 
 6.1 Quality Control.
Hospira shall apply its quality control procedures and in-plant quality control checks on the manufacture of Product for Revance in the same manner as Hospira applies such procedures and checks to products of similar nature manufactured for sale by
Hospira but using no less than industry standard quality control procedures and reasonable care. In addition Hospira will test and release Product in accordance with the test methods described in Exhibit 6.1 to ensure that Product
conforms to the Product Specifications. The parties may change the test methods from time to time by mutual agreement. 
 6.2
Quality Agreement. The parties shall enter into a quality agreement substantially in the form of the agreement attached hereto as Exhibit 6.2 within one-hundred and twenty (120) days following the Effective Date
(“Quality Agreement”). 
 6.3 Audit Rights.  

(a) General Audit. Upon [***] prior written notice to Hospira, Revance shall have the right to have representatives visit
the [***] facility during normal business hours to review Hospira’s manufacturing operations relating to the Product and assess its compliance with Applicable Law, cGMP and quality assurance standards and to discuss any related issues with
Hospira’s manufacturing and management personnel. Hospira shall provide Revance with copies 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10.

 
of Hospira’s manufacturing records relating to the Products for the purposes of assuring Product quality and compliance with agreed-upon manufacturing procedures. Subject to
Section 6.3(b), such general audits shall [***]. 
 (b) For Cause Audits. Revance shall also have the right
to conduct “for-cause” audits to address significant product or safety concerns as discovered through Product failures related to Hospira’s manufacture of the Product. Product failures would include, without limitation, issues related
to stability, out of specification, sterility, labeling or container integrity. Revance shall notify Hospira in writing in advance of the audit and thereafter, Revance and Hospira shall mutually determine the timing of the audit. Each for-cause
audit shall be [***]. 
 (c) Confidential Information in Audits. Audits by Revance or its designees may involve
the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 10 hereof. The results of such audits and inspections shall be considered Confidential Information under
Article 10 and shall not be disclosed to third parties, including, but not limited to, the FDA, unless required by law and only then upon prior written notice to Hospira. Hospira also agrees to allow the FDA to conduct any audit which
the FDA requires and Hospira agrees to reasonably cooperate with the FDA in connection with such audit. Revance shall have the right to be on site during a pre-approval inspection for the Product, but may only directly participate in the inspection
if requested by the FDA or Hospira. However, if any additional inspections are requested or required by or for any other Regulatory Authority, Hospira shall be entitled to an additional fee of [***] per each such Regulatory Authority inspection.

 6.4 Notification of Complaints. Revance shall notify Hospira promptly of any Product complaints involving
Hospira’s manufacture or packaging to allow Hospira to evaluate the complaints and assist Revance in responding to such complaints. Hospira shall notify Revance promptly of any Product complaints involving Hospira’s manufacture or
packaging, and any other complaints relevant to the subject matter of this Agreement, to allow Revance to evaluate the complaints and assist Hospira in responding to such complaints. 

6.5 Product Recalls. 
 (a) In the event (i) any Regulatory Authority or other national government authority issues a request, directive or order that Product be recalled; (ii) a court of competent jurisdiction orders
such a recall, or (iii) Revance reasonably determines that Product should be recalled, the parties shall take all appropriate corrective actions, and shall cooperate in any governmental investigations surrounding the recall. 

(b) In the event that such recall results from the breach of Hospira’s express warranties under Section 7.2(a) or
(b), or other obligations hereunder, Hospira agrees that it shall be responsible for promptly replacing the quantity of Products that were recalled at no cost to Revance (without the Components that were the subject of the recall) or
reimbursing Revance for the cost of the Products that were recalled. In addition, Hospira agrees that it shall be responsible for the administrative expenses of any recall, provided that Hospira shall not pay more than [***]. For purposes of this
Agreement, the administrative expenses of the recall shall include, but not be limited to, the expenses of notification and destruction or return of the recalled Product, and any costs associated with the distribution of the replacement Product, but
shall not include lost profits of either party. To the extent that the recall does not result from the breach of 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11.

 
Hospira’s express warranties or other obligations under this Agreement, Revance shall be responsible for the expenses of the recall. Nothing in this Section is intended to limit
Hospira’s obligations to indemnify Revance for Third Party claims under Section 7.3. 
 ARTICLE 7.
WARRANTIES; COVENANTS AND INDEMNIFICATION 
 7.1
Revance’s Warranties. Revance represents and warrants to Hospira that: 
 (a) all Specifications, including
Product Specifications Revance provides to Hospira shall conform to the appropriate NDA that Revance files with the relevant Regulatory Authorities; 
 (b) Revance’s performance of its obligations under this Agreement will not result in a material violation or breach of any agreement, contract, commitment or obligation to which Revance is a party or
by which it is bound and will not conflict with or constitute a default under its corporate charter or bylaws; 
 (c) it will
not sell Product into any regulatory jurisdiction unless and until it receives the necessary Regulatory Authority approvals; and it will not sell Product outside of the United States without Hospira’s prior written consent; 

(d) neither the Product nor the Product Specifications nor their use infringes or will infringe, misappropriate or violate any
intellectual property or proprietary rights of any Third Party, including but not limited to patent, copyright, trademark or trade secret rights anywhere in the world. 
 7.2 Hospira’s Warranties and Covenants. Hospira represents and warrants to Revance that: 
 (a) all Product Hospira delivers to Revance pursuant to this Agreement shall, at the time of delivery, not be adulterated or misbranded within the meaning of the Act or within the meaning of all
Applicable Law in which the definitions of adulteration and misbranding are substantially the same as those contained in the Act, as the Act and such laws are constituted and effective at the time of delivery and will not be an article which may not
under the provisions of Sections 404 and 505 of the Act be introduced into interstate commerce; 
 (b) all Product Hospira
delivers to Revance pursuant to this Agreement shall, at the time of delivery, be free from defects in material and workmanship and shall be manufactured: (i) in accordance and conformity with the Product Specifications; and (ii) in
compliance with all Applicable Laws, including those relating to the environment, food or drugs and occupational health and safety, including, without limitation, those enforced or promulgated by the FDA (including, without limitation, compliance
with cGMP); 
 (c) Hospira’s performance of its obligations under this Agreement will not result in a material violation or
breach of any agreement, contract, commitment or obligation to which Hospira is a party or by which it is bound and will not conflict with or constitute a default under its corporate charter or bylaws, or violate any Applicable Law; 

(d) All services and other work under this Agreement will be performed in a professional, diligent and workmanlike manner in accordance
with standard industry practices; 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12.

 (e) the Hospira’s manufacturing processes not specifically required by the Product
Specifications will not infringe, misappropriate or violate any intellectual property or proprietary rights of any Third Party; and 
 (f) that Hospira does not use nor will it use in the future use in any capacity the services of any person debarred under Section (a) or (b) of 21 U.S.C. Section 335a in performing its
obligations under this Agreement. 
 (g) Subject to Section 7.3, the replacement provisions of
Section 4.10(c) shall be Revances’s sole and exclusive remedy for nonconforming or defective Product. 
 (h)
NEITHER PARTY MAKES ANY OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE ARE HEREBY DISCLAIMED. 
 7.3 Indemnification by Hospira. Except to the extent caused by the
negligence or willful misconduct of Revance, its Affiliates, or their respective officers, directors or employees, Hospira shall indemnify and hold harmless Revance, its Affiliates, officers, directors and employees from and against all claims,
causes of action, suits, costs and expenses (including reasonable attorney’s fees), losses or liabilities of any kind related to this Agreement and asserted by third parties to the extent such arise out of or are attributable to:
(a) Hospira’s breach of any representation or warranty set forth in Section 7.2(a) or Section 7.2(b); (b) any violation of any proprietary right of any Third Party relating to Hospira’s manufacturing
processes used in the manufacture of Product pursuant to this Agreement (excluding the Product or Product Specifications); or (c) any negligent or wrongful act or omission on the part of Hospira, its employees, agents or representatives and
which relate to Hospira’s performance hereunder. 
 7.4 Indemnification by Revance. Except to the extent
caused by the negligence or willful misconduct of Hospira, its Affiliates, or their respective officers, directors or employees, Revance shall indemnify and hold harmless Hospira, its Affiliates, officers, directors and employees harmless from and
against all claims, causes of action, suits, costs and expenses (including reasonable attorney’s fees), losses or liabilities of any kind related to this Agreement and asserted by Third Parties to the extent such arise out of or are
attributable to: (a) Revance’s breach of any representation or warranty set forth in Section 7.1; (b) any violation of any proprietary right of any Third Party relating to the Product Specifications or Product, other than
Hospira’s manufacturing processes (to the extent not specifically required by the Specifications) used in the manufacture of Product pursuant to this Agreement; (c) the use of or lack of safety or efficacy of Product or RT001; and
(d) any negligent or wrongful act or omission on the part of Revance, its employees, agents or representatives and which relate to Revance’s performance hereunder. 
 7.5 Conditions of Indemnification. If either party seeks indemnification from the other hereunder, it shall promptly give notice to the other party of any such claim or suit threatened, made
or filed against it which forms the basis for such claim of indemnification and shall cooperate fully with the other party in the investigation and defense of all such claims or suits. The indemnifying party shall have the option to assume sole
control over the other party’s defense in any such claim or suit with counsel reasonably satisfactory to the other party. No settlement or compromise shall be binding on a party hereto without its prior written consent, such consent not to be
unreasonably withheld. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13.

 7.6 No Consequential Damages. EXCEPT FOR (1) VIOLATION OF CONFIDENTIALITY
OBLIGATIONS HEREIN, AND (2) THE INDEMNITY OBLIGATIONS HEREIN, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES RESULTING FROM ANY BREACH OF THIS AGREEMENT EVEN IF THE
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 ARTICLE 8. INTELLECTUAL PROPERTY
RIGHTS 
 8.1 Hospira’s Proprietary Rights. Except as expressly set forth herein, Hospira
has granted no license, express or implied, to Revance to use Hospira proprietary technology, know-how or other proprietary rights: (a) existing prior to the Effective Date; or (b) developed by or for Hospira on or after the Effective Date
outside the scope of the Project or Stability Work undertaken by Hospira pursuant to this Agreement (or the Letter Agreement). 

8.2 Revance’s Proprietary Rights. Revance has granted no license, express or implied, to Hospira to use Revance’s
proprietary technology, know-how or other proprietary rights other than as necessary for Hospira to perform its obligations for the purposes of this Agreement. Revance shall be the sole owner of any proprietary technology, know-how or other
proprietary rights developed by Hospira pursuant to the Project the Letter Agreement or Stability Work (“Project Inventions”) and Revance shall be entitled to apply for patent protection on such Project Inventions at
Revance’s expense and risk. Hospira hereby assigns and agrees to assign to Revance all right, title and interest in and to the Project Inventions (including all related intellectual property rights) and agrees to reasonably cooperate with
Revance, at Revance’s sole cost, to perfect such assignments. However, Revance shall grant to Hospira, and does hereby grant to Hospira, a non-exclusive, royalty-free, fully-paid, worldwide, perpetual license under such Project Inventions to
make, have made, use, offer for sale, sell, and/or import drugs and products, [***]. 
 ARTICLE 9. TERM
AND TERMINATION 
 9.1 Term. This Agreement shall commence on the Effective Date
and, unless earlier terminated as provided below, shall expire at [***] (“Initial Term”). Unless otherwise terminated in accordance with this Article 9, this Agreement shall be automatically extended for
additional terms of [***] (each, a “Renewal Term”) and may be terminated anytime after the Initial Term by either party providing the other with at least [***] prior written notice of termination. 

9.2 Termination of the Project. Either party wishing to terminate the Project shall request in writing a pre-termination
consultation with the other party to review potential concerns and to make reasonable efforts to continue with this Agreement. Upon [***] following said consultation, either party may terminate the Project upon [***] prior written notice to the
other party if the terminating party determines in good faith that the development of the Product is not technically feasible using commercially reasonable efforts. If the Project is terminated, Hospira shall advise Revance of Hospira’s actual
development costs on the Project incurred prior to such termination. Revance shall pay Hospira for all pre-approved reasonable and documented development costs incurred to the date the termination notice is received. The foregoing provisions of this
Section 9.2 shall only apply [***]. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 14.

 9.3 Failure to Obtain Regulatory Approval. Either party may terminate this
Agreement by giving to the other party twelve (12) months’ prior written notice if the Product has not received FDA regulatory approval by [***]. 
 9.4 General Termination Rights. Either party may terminate this Agreement as follows: 
 (a) Immediately by providing written notice upon the bankruptcy or the insolvency of the other party; or 
 (b) By giving to the other party ninety (90) days’ prior written notice upon the breach of any warranty or any other material provision of this Agreement by the other party if the breach is not
cured within ninety (90) days after written notice thereof to the party in default. 
 9.5 Accrued Payment
Obligations. Upon termination pursuant to this Article 9 (other than by Revance pursuant to Section 9.4), Revance shall reimburse Hospira for Hospira’s pre-approved cost of all Components purchased and on hand or
on order, if such Components were ordered by Hospira based on Purchase Orders or Revance’s estimates of its requirements of Product during the current Finn Order Period, and such supplies cannot be reasonably used by Hospira for other purposes.
Hospira shall invoice Revance for all amounts due hereunder and shall provide all such Revance paid for Components to Revance at Revance’s cost. Payment shall be made pursuant to Section 4.9. 

9.6 Return of Inventory. In the event of any termination, Hospira shall return any remaining inventory of Product to
Revance at Revance’s expense plus the price for such Products determined in accordance with Section 4.9, unless such termination shall have been as a result of a breach of this Agreement by Hospira, in which case such inventory shall be
returned at Hospira’s expense but Revance shall still be required to pay the price for such Products determined in accordance with Section 4.9. 
 9.7 Survival. Expiration or early termination of this Agreement shall not relieve either party of any obligations that it may have incurred prior to expiration or early termination and all
covenants and agreements contained in this Agreement, which by their terms or context are intended to survive, will continue in full force and effect for a period of three (3) years unless a different time period is indicated in this Agreement;
including without limitation Articles 7, 8, 10, 11 and Sections 2.3, 6.4, 6.5, 9.5, 9.6, and 9.7. 
 ARTICLE 10.
CONFIDENTIAL INFORMATION 
 10.1 Nondisclosure. It is contemplated that in the
course of the performance of this Agreement each party may, from time to time, disclose Confidential Information to the other. Hospira agrees that, except as expressly provided herein, it shall not disclose Confidential Information received from
Revance, and shall not use Confidential Information disclosed to it by Revance, for any purpose other than to fulfill Hospira’s obligations hereunder. Revance agrees that, except as expressly provided herein, it shall not disclose Confidential
Information received from Hospira, and shall not use Confidential Information disclosed to it by Hospira, for any purpose other than to fulfill Revance’s obligations hereunder. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 15.

 10.2 Exceptions to Duty of Nondisclosure. Notwithstanding the above, nothing
contained in this Agreement shall preclude Revance from utilizing Confidential Information as may be necessary in prosecuting the patent rights of Revance pursuant to Article 8, obtaining governmental regulatory approvals, manufacturing
Product pursuant to the terms and conditions of this Agreement, or complying with Applicable Laws or court orders (provided that the party disclosing such information uses reasonable efforts to seek confidential treatment of such information, except
as required to file and prosecute such patent applications), or exercising its other express rights in this Agreement. The obligations of the parties relating to Confidential Information shall expire ten (10) years after the termination of this
Agreement. 
 10.3 Public Announcements. Neither party shall make any public announcement concerning the
transactions contemplated herein, or make any public statement which includes the name of the other party or any of its Affiliates, or otherwise use the name of the other party or any of its Affiliates in any public statement or document, except as
may be required by law or judicial order, without the written consent of the other party, which consent shall not be unreasonably withheld. Subject to any legal or judicial disclosure obligation, any such public announcement proposed by a party that
names the other party shall first be provided in draft to the other party. 
 10.4 Injunctive Relief. The parties
acknowledge that either party’s breach of this Article 10 may cause the other party irreparable injury for which it would not have an adequate remedy at law. In the event of a breach, the non-breaching party may be entitled to
injunctive relief in addition to any other remedies it may have at law or in equity 
 ARTICLE 11.
MISCELLANEOUS 
 11.1 Force Majeure and Failure of Suppliers. 

(a) Excusable Delay. Any delay in the performance of any of the duties or obligations of either party hereto (except the
payment of money) shall not be considered a breach of this Agreement and the time required for performance shall be extended for a period equal to the period of such delay, provided that such delay has been caused by or is the result of force
majeure events, including any acts of God, acts of the public enemy, insurrections, riots, embargoes, labor disputes, including strikes, lockouts, job actions, boycotts, fires, explosions, floods, industry shortages of material or energy, or other
unforeseeable causes beyond the control and without the fault or negligence of the party so affected. The affected party shall give prompt notice to the other party of such cause, and shall take promptly whatever reasonable steps are necessary to
relieve the effect of such cause. 
 (b) Transfer of Production. If (a) Hospira becomes subject to an event
of force majeure that prevents Hospira from supplying in accordance with this Agreement; (b) there is a Failure to Supply under Section 5.9; (c) Revance terminates the Agreement in accordance with Section 9.4;
(d) Hospira ceases to conduct business or files or has filed against it a petition seeking reorganization or a similar procedure; or (e) a receiver, trustee, or similar officer is appointed for the business or property of Hospira, or
Hospira makes an assignment for the benefit of creditors (“Trigger Event”); Hospira shall reasonably cooperate and assist Revance 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 16.

 
with the transfer of production (or establishment of a second source) and the parties shall mutually agree on and implement the agreed-upon action plan to transfer production of Product
(including without limitation, providing all batch records, data, know-how and other information related to Hospira’s manufacturing process with respect to the Product) to another manufacturer designated by Revance. The parties shall, after the
execution of this Agreement and at the request of either party, meet to discuss and define such an action plan. In connection with any Transfer of Production under this Section 11.1(b), Hospira hereby grants Revance a limited,
non-transferable (except as provided in Section 11.4), non-exclusive, perpetual, irrevocable, fully paid right and license in the Territory, under Hospira’s relevant intellectual property rights (if any) that are being utilized by
Hospira to manufacture Product at the time Trigger Event occurs, to make, have made, use, sell, offer for sale, import and distribute Product in the Territory, and Revance shall be relieved of (1) any of its obligation under
Section 4.1 to purchase and take delivery of its total requirements of the poloxamer cartridges exclusively from Hospira and (ii) any minimum purchase obligations under Section 5.7. 

11.2 Notices. All notices hereunder shall be delivered as follows: (a) personally; (b) by facsimile and confirmed
by first class mail (postage prepaid); (c) by registered or certified mail (postage prepaid); or (d) by overnight courier service, to the following addresses of the respective parties: 

 

							
	If to Revance:	 		  	With a copy to:	  	
				
	Revance Therapeutics Inc	 		  	(same address)	  	
	7555 Gateway Blvd	 		  	  
	  	
	Newark, CA 94560	 		  	  
	  	
	Attention:         Chief Exec Officer	 		  	Attention:         Chief Financial Officer	  	
	Facsimile:          (510) 742-3401	 		  	Facsimile:          (510) 742-3401	  	
				
	If to Hospira:	 		  	With copy to:	  	
				
	Hospira, Inc.	 		  	Hospira, Inc.	  	
	275 North Field Drive	 		  	Building Hl; Department NLEG	  	
	Lake Forest, Illinois 60045	 		  	275 N. Field Drive	  	
	Attention:         V.P. Contract Manufacturing	 		  	Lake Forest, IL 60045	  	
	Facsimile:          (224) 212-3210	 		  	Attention:         General Counsel	  	
		 		  	Facsimile:          224-212-2086	  	

 Notices shall be effective upon receipt if personally delivered or delivered by facsimile and confirmed
by first class mail, on the third business day following the date of registered or certified mailing or on the first business day following the date of or delivery to the overnight courier. A party may change its address listed above by written
notice to the other party. 
 11.3 Choice of Law. This Agreement shall be construed, interpreted and governed by
the laws of the State of Delaware, excluding its choice of law provisions. The United Nations Convention on the International Sale of Goods is hereby expressly excluded. 
 11.4 Assignment. Neither party shall assign this Agreement nor any part thereof without the prior written consent of the other party; provided, however: (a) either party may assign this
Agreement to one of its wholly-owned subsidiaries or its parent corporation without 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 17.

 
such consent; and (b) either party, without such consent, may assign this Agreement in connection with the transfer, sale or divestiture of substantially all of its business to which this
Agreement pertains or in the event of its merger or consolidation with another entity. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve any party of responsibility for the
performance of any accrued obligation which such party then has hereunder. 
 11.5 Entire Agreement. This
Agreement, together with the Exhibits referenced and incorporated herein, constitute the entire agreement between the parties concerning the subject matter hereof and supersede all written or oral prior agreements or understandings with respect
thereto, including the Letter Agreement. If there is any conflict, discrepancy, or inconsistency between the terms of the Quality Agreement and any Statement of Work, the Agreement or other form used by the parties with regards to quality assurance,
the Quality Agreement will control; in all other cases, the Agreement will control. 
 11.6 Severability. This
Agreement is subject to the restrictions, limitations, terms and conditions of all applicable governmental regulations, approvals and clearances. If any term or provision of this Agreement shall for any reason be held invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or provision, to the extent the same shall have
been held to be invalid, illegal or unenforceable, had never been contained herein. 
 11.7 Waiver-Modification of
Agreement. No waiver or modification of any of the terms of this Agreement shall be valid unless in writing and signed by authorized representatives of both parties. Failure by either party to enforce any such rights under this Agreement
shall not be construed as a waiver of such rights, nor shall a waiver by either party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances. 

11.8 Insurance. Each party will procure and maintain, at its own expense, for the duration of the Agreement, and for five
(5) years thereafter if written on a claims made or occurrence reported form, the types of insurance specified below with carriers rated A- VII or better with A. M. Best or like rating agencies: 

(a) Workers’ Compensation accordance with applicable statutory requirements and shall provide a waiver of subrogation in favor of
the other party; 
 (b) Employer’s Liability with a limit of liability in an amount of not less than [***]; 

(c) Commercial General Liability including premises operations, products & completed operations, blanket contractual liability,
personal injury and advertising injury including fire legal liability for bodily injury and property damage in an amount not less than [***] per occurrence and [***] in the aggregate; 

(d) Commercial Automobile Liability for owned, hired and non-owned motor vehicles with a combined single limit in an amount not less than
[***] each occurrence; and 
 (e) Excess Liability including products liability with a combined single limit in an amount of not
less than [***] per occurrence and in [***] in the aggregate. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 18.

 Each party shall include the other party and its Affiliates, directors, officers, employees
and agents as additional insureds with respect to Commercial General Liability, Commercial Automobile Liability and Excess Liability covering its obligations under this Agreement, but only as their interest may appear by written contract. Prior to
commencement of services, and annually thereafter, each party shall furnish to the other party certificates of insurance evidencing the insurance coverages stated above and shall endeavor to provide at least thirty (30) days written notice to
the other party prior to any cancellation, non-renewal or material change in said coverage. In the case of cancellation, non-renewal or material change in said coverage, each party shall promptly provide to the other party a new certificate of
insurance evidencing that the coverage meets the requirements in this Section. Each party agrees that its insurance shall act as primary and noncontributory from any other valid and collectible insurance maintained by the other party. Each party
may, at its option, satisfy, in whole or in part, its obligation under this Section through its self- insurance program. 
 11.9
Exhibits. All Exhibits referred to herein are hereby incorporated by reference. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 19.

 IN WITNESS WHEREOF, the
parties intending to be bound by the terms and conditions hereof have caused this Agreement to be signed by their duly authorized representatives as of the date first above written. 

 

							
	HOSPIRA WORLDWIDE, INC.	 	REVANCE
				
	By:	  	 /s/ Anthony Cacich
	 	By:	 	 /s/ Curtis Ruegg

	Name:	  	Anthony Cacich	 	Name:	 	Curtis Ruegg
	Title:	  	VP&GM Contract Manufacturing Services	 	Title:	 	Exec VP, R&D

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 1.9 

Product Specifications 
  

			
	 Finished Product Test
	  	Specification
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 2.1 

Project Development Activities 
  

																							
	 Project Initiation
	  	Req.	 	  	Not.
Req.	 	  	N/A	 	  	Responsibility	 	  	Comment
	  	  	  	  	Hospira	 	  	Client	 	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	
	 Price:
	  	 	[***]	  	  				  				  				  				  	
	 Payment:
	  	 	[***]	  	  				  				  				  				  	
	 Timing:
	  	 	[***]	  	  				  				  				  				  	

  

																									
	 Equipment
	  	Req.	 	  	Not.
Req.	 	  	N/A	 	  	Responsibility	 	  	Comment	 
	  	  	  	  	Hospira	 	  	Client	 	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Price:
	  	 	[***]	  	  				  				  				  				  	 	[***]	  

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

																									
	 Product Development
	  	Req.	 	  	Not.
Req.	 	  	N/A	 	  	Responsibility	 	  	Comment	 
	  	  	  	  	Hospira	 	  	Client	 	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 Price:
	  	 	[***]	  	  				  				  				  				  			
	 Payment:
	  	 	[***]	  	  				  				  				  				  			
	 Timing:
	  	 	[***]	  	  				  				  				  				  			

  

																													
	 Engineering and Registration Batch Production
	  	Req.	 	  	Not.
Req.	 	  	N/A	 	  	Responsibility	 	  	Price	 	  	Comment	 
	  	  	  	  	Hospira	 	  	Client	 	  	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Payment:
	  	 	[***]	  	  				  				  				  				  				  			
	 Timing:
	  	 	[***]	  	  				  				  				  				  				  			

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

																									
	 Process Validation and Review
	  	Req.	 	  	Not.
Req.	 	  	N/A	 	  	Responsibility	 	  	Comment	 
	  	  	  	  	Hospira	 	  	Client	 	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 Price:
	  	 	[***]	  	  				  				  				  				  			
	 Payment:
	  	 	[***]	  	  				  				  				  				  			
	 Timing:
	  	 	[***]	  	  				  				  				  				  			

  

																									
	 Regulatory Filing Preparation and Submission
	  	Req.	 	  	Not.
Req.	 	  	N/A	 	  	Responsibility	 	  	Comment	 
	  	  	  	  	Hospira	 	  	Client	 	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 Price:
	  	 	[***]	  	  				  				  				  				  	 	[***]	  
	 Payment:
	  	 	[***]	  	  				  				  				  				  			
	 Timing:
	  	 	[***]	  	  				  				  				  				  			

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

																									
	 Commercialization
	  	Req.	 	  	Not.
Req.	 	  	N/A	 	  	Responsibility	 	  	Comment	 
	  	  	  	  	Hospira	 	  	Client	 	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 Price:
	  	 	[***]	  	  				  				  				  				  			
	 Payment:
	  	 	[***]	  	  				  				  				  				  			
	 Timing:
	  	 	[***]	  	  				  				  				  				  			

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 2.3 

Payment Schedule 
 Payment
of the Development Fee shall be in accordance with the following schedule: 
 [***] 
 Payment of the Development Stability Studies will be paid in accordance with the following schedule: 
 [***] 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 2.7 

Development Supplies Pricing 
 PoloxamerCartridge 
  

					
	 Batch Type
	  	Price Batch	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

 Development Stability Program Pricing 

 

					
	 Program
	  	Cost	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

 Stability Program for [***] consists of the following: 

[***] 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 4.9 

Product Prices 

Commercial Product 
  

									
	 Presentation
	  	Batch Size	  	Package Configuration	  	Units Per Year	  	Price Pet Unit
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]

 Commercial Stability Testing 
 Stability Program for [***] consists of the following: 
 [***]

  

			
	 Stability Type
	  	Price
	 [***]
	  	[***]

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 6.1 

Product Test Methods 

[***] 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT 6.2 

Form of Quality Agreement 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 DRUG 

QUALITY TECHNICAL AGREEMENT 

Version 01 
 This
Quality Technical Agreement is between: 
 Hospira Worldwide, Inc. 

275 North Field Drive 
 Lake Forest, IL 60045 
 – And – 

Revance Therapeutics, Inc. 
 7555 Gateway Blvd. 
 Newark, CA 94560 

For the manufacture of a diluent cartridge at [***] Hospira facility. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2. 

 EFFECTIVE DATE 

The Effective Date of this Quality Agreement shall be the date of last signature (the “Effective Date”). 

SCOPE OF THE QUALITY TECHNICAL AGREEMENT 

This Quality Technical Agreement (QTA) defines the key principles of cooperation between Hospira Worldwide, Inc. (“Hospira”) and
Revance Therapeutics, Inc (Revance Therapeutics) with respect to technical and Quality Assurance GMP responsibilities. 
 This
document outlines the functions and responsibilities for the manufacture and quality of those clinical and commercial Product(s) identified in Appendix 1. These products will only contain excipient ingredients for use as diluent and will not contain
API. Primary Contact information (if applicable) is detailed in Appendix 2, which may be added to or revised as necessary. 

This QTA shall commence on the Effective Date and shall remain in effect until the latest of: (i) the expiration date of the last
Batch of Product produced by HOSPIRA for commercial distribution; (ii) completion of any ongoing stability studies; or (iii) [***] after the termination of the Development and Supply Agreement. This QTA shall be reviewed, amended as
needed, and approved, minimally within [***] of the most current approval date. 
 In the event of a conflict between the
provisions of this QTA and the relevant Development and Supply Agreement, the provisions of this QTA shall control solely for quality-related responsibilities as set forth herein, and the Development and Supply Agreement shall control for all other
provisions. This QTA is supplemental to the Development and Supply Agreement and the provisions of that agreement shall govern the activities hereunder to the extent they do not conflict with the terms of this QTA. 

All regulatory obligations contained herein that are required of either Party or both Parties by an applicable Regulatory Authority shall
survive termination of this QTA. 
 OBJECTIVE OF THE QUALITY
TECHNICAL AGREEMENT 
 The objective of this Quality Technical Agreement is to set out the
technical arrangements for ensuring that the manufacture, quality control, and release of the Product complies with current good manufacturing practices as set forth in 21 CFR Part 11, Parts 210 & 211 in the United States, European
Directives 2003/94/EC and 2001/83/EC and Volume IV of the rules governing medicinal products in the European Community and Canadian Regulations Health Canada- Health Products and Food Branch Inspectorate Good Manufacturing Practices (GMP) Guidelines
GUI-0001, if applicable and related legislation and/or as required for any clinical studies. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  

 PROCEDURES FOR REVISION 

This QTA and applicable appendices can be modified as needed with the approval of the responsible Quality management (or designate) of
both parties. This QTA must be modified if any item fails to meet future revisions of US 21 CFR Part 11 and Parts 210 and 211 or the Canadian and EU Directives including Volume IV of the rules governing medicinal products in the European Community
(if applicable), and other applicable regulations and guidelines. If revisions to this QTA are required other than to the Contact List (Appendix 2) both parties must approve changes in writing. Changes to the Contact List may be updated by either
party from time to time by written or e-mail communication. Such updates shall not require formal approval or re-approval of the Quality Technical Agreement. This QTA will utilize version control. 

DEBARMENT 

Hospira warrants and represents that it is not debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. 335[a] (the
“Generic Drug Enforcement Act”), and that it has not been convicted of a crime for which it could be debarred under the Generic Drug Enforcement Act. In connection with the Product, Hospira further warrants and represents that it shall not
use in any capacity the services of any person debarred under the Generic Drug Enforcement Act, or convicted of a crime for which a person can be debarred under the Generic Drug Enforcement Act. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2. 

 APPROVAL SIGNATURES 

 

			
	 Hospira Worldwide, Inc.

275 North Field Drive
 Lake Forest, IL
60045
	  	 Revance Therapeutics, Inc
 7555 Gateway Boulevard
 Newark, CA 94560

		
	Plant Quality - Site	  	Revance Therapeutics
	Signature:	  	Signature:
		
	 /s/ Randy Edwards
	  	 /s/ Philip Perotti

	Date:	  	Date:
		
	 5-24-2011
	  	 24 May 11

	Title: Customer Quality Manager	  	Title: Senior Manager, Quality
	  
	  	  

	Name: Randy Edwards	  	Name: Philip Perotti
		
	 Corporate Quality

Signature:
  

/s/ Natasha Rivas
	  	 Revance Therapeutics 
 Signature:
  
                      

	Date:	  	Date:
		
	 24 May 2011
	  	  

	Title: Quality Manager, One2One	  	Title: Manager, Manufacturing and Process
	  
	  	  

	Name: Natasha Rivas	  	Name: Savitha Venkatesh
		
		  	 Revance Therapeutics
 Signature:

		
		  	 /s/ Sharon L. Hall for Curtis Ruegg

		  	Date:
		
		  	 25 May 11

		  	Title: EVP Research and Development
		  	  

		  	Name: Curtis Ruegg

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 3. 

 DEFINITIONS 
 The following terms used herein shall have the following meanings: 

“Adverse Drug Experience (ADE)”: Per 21CFR 314 and 21CFR312: “Any adverse event associated with the use of a
drug in humans, whether or not considered drug related, including the following: An adverse event occurring in the course of the use of a drug product in professional practice; an adverse event occurring from drug overdose whether accidental or
intentional; an adverse event occurring from drug abuse; an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action. 
 “Annual Product Quality Review (APQR)”: Also known as Annual Product Review (APR), is a process of reviewing the product quality of finished products in order to determine if
current processes have inherent capability to reproduce results within specification limits and to determine if manufacturing/packing processes and the corresponding quality systems are in control. 

Annual Report: as required by 21CFR312 and 314 or any other regulatory authority requiring periodic updates 

“Applicable Laws”: All laws, ordinances, rules and regulations within the Territory as defined within the
Development and Supply Agreement applicable to the Processing of “Product” and the rights and obligations of Hospira or Revance Therapeutics as the context requires, including, without limitation, (i) all applicable federal, state and
local laws and regulations of each Territory; (ii), 21 CFR Part 11 and Parts 210 and 211, and (iii) Canadian and EU Directives including Volume IV of the rules governing medicinal products in the European Community, and (iv) the laws and
regulations of other applicable Regulatory Authorities. 
 “BLA”: Biological License Application

 “BPDR”: Biologic Process Deviation Report, as defined by FDA in 21CFR 600.14. 

“Batch Adjustment”: Procedure used to adjust the bulk Product solution within the range of an in-process control
point. 
 “Batch Record”: The document wherein are contained all of the details pertaining to the
manufacture of the Product. These are considered Proprietary Information and are not to be divulged to a third party without prior written permission. 
 “cGMPs”: The recognized pharmaceutical regulations and other regulations as well as requirements of the authorities, the requirements of the directive 2003/94/EC, the requirements
of the EC GMP Guide and the GMP requirements of the US Food and Drug Administration (FDA) each in its current version in so far as these affect the quality of the Product(s). 
 “Commodity Specifications or Raw Material Monograph”: A composite of the specifications and testing instructions for raw materials. It describes the chemical, physical,
microbiological and biological requirements of the raw materials. It also contains testing instructions that are used to test the raw materials. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 4. 

 “Complaint”: Any direct written, electronic or oral communication of
dissatisfaction that alleges deficiencies related to the identity, quality, potency, labeling, purity, stability or appearance. Also includes potential package damage issues. 
 “Development and Supply Agreement”: The contract between the two parties describing all commercial aspects pertaining to the Product. This Quality Technical Agreement is intended
as an annex to the Development and Supply Agreement. 
 “EMA”: European Medicines Agency. 

“EIR”: Establishment Inspection Report 
 “Exception/Deviation”: a departure or deviation from a defined policy, procedure, specification, or regulatory requirement, which may affect the safety, identity, strength, purity
or quality of the Product. As defined by the levels below: 
 “Low”: [***]. 

“Medium”: [***]. 
 “High”: [***]. 
 “Exception Report
(ER)”: A Hospira term for a formally tracked report that documents the Investigation for an Exception/Deviation to an established standard, which may affect the safety, identity, strength, purity or quality of the Product. 

“Facilities”: Means Hospira Inc., depending on Product manufacturing and/or testing location, see Appendix 1.

 “FDA”: United States Food and Drug Administration, and any successor entity thereto. 

“Field Alert”: Notification of a potential safety threat for drug products in commercial distribution within the
United States, which are marketed under an approved marketing application, as defined by FDA in 21CFR 314.81 (b)(1). 

“Immediately”: [***] or within [***]. 
 “IND”: Investigational New Drug Application 

“Marketing Application/ Marketing Authorization Application” (MA/MAA): An application for marketing authorization
which has not yet been approved by the FDA or other Regulatory Authority, including without limitation, FDA Biological License Application, FDA New Drug Application and other similar marketing authorizations promulgated by Regulatory Authorities.

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5. 

 “Marketing Authorization”:Any approved Marketing Application,
including without limitation, FDA Biological License Application, FDA New Drug Application, and other similar marketing authorizations promulgated by Regulatory Authorities. 
 “Materials”: All excipients, printed or unprinted commodities which are used during the manufacturing or finishing process of product. 

“Out of Specification” (OOS): Refers to a test result which is not within the specified range for that parameter.

 “Process” or “Processing”: The compounding, filling and/or packaging of the
Finished Product in accordance with the specifications and the terms and conditions set forth in the applicable approved agreements and this QTA, including validation, maintenance and testing activities associated therewith. 

“Product”: All Product(s) listed in Appendix 1. 

“Proprietary”: Exclusive property of Hospira. 

“QTA”: Shall mean Quality Technical Agreement. 

“Recall”: Recall of commercial or clinical Finished Product and/or retrieval of material that has the potential
to jeopardize the health or safety of patients or is non-compliant with the applicable legislation or cGMP guidelines. 

“Re-inspection”: A visual or mechanical evaluation performed to remove or correct defective units for which the
re-inspection process is not expected to have an adverse effect on Product quality. Re-inspection will involve the use of an exception report, except where standard procedure allows for such routine activity in the course of normal processing.

 “Reprocessing”: Duplication of a step or steps currently in the manufacturing formula in order to
bring Product into conformance with specifications and which will not alter the safety, identify, strength, quality, or purity of Product beyond the established requirements. All reprocessing must be documented per pre-approved documentation
requirements and appended to the exception document. 
 “Rework”: Any additional steps taken to process
a batch (other than re-inspection) to bring it into conformance with the specifications and which will not alter the safety, identity, strength, quality, or purity of Product beyond the established requirements. All rework, where applicable, must be
documented per pre-approved rework documentation requirements and appended to the exception document. 

“Specification”: The quality standards, including tests, analytical procedures and acceptance criteria that are
established to confirm the quality of Product. Analogous to “Monograph” in the Hospira [***] quality system. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6. 

 “Standard Operating Procedures” (SOPs): The Standard Operating
Procedures in effect at Revance Therapeutics or Hospira which have been approved by the applicable Quality Assurance department. 
 “Territory” or “Territories”: shall mean those countries and territories for which the Product is being manufactured and within which the Product will be
distributed. 
 “Third Party”: Shall mean a person or entity other than Revance Therapeutics or Hospira
or their respective affiliates. 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7. 

 RESPONSIBILITY CHECKLIST 

Responsibility for each activity is assigned to either party in the appropriate box in the checklist that follows. Both groups will
perform the activities defined herein in accordance with internal Standard Operating Procedures applicable to such activities. 
  

							
	 	  	 Responsibility
	  	Hospira	 	Revance
Therapeutics
	 1.0
	  	Quality Agreements
	[***]	  	[***]	  	[***]	 	[***]
	 2.0
	  	REGULATORY AUTHORIZATIONS & cGMP REQUIREMENTS
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	 3.0
	  	Regulatory Actions & Inspections
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
		  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8. 

							
	 	  	 Responsibility
	  	Hospira	 	Revance
Therapeutics
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	4.0	  	Audits
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	5.0	  	Materials
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	6.0	  	Labeling
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	7.0	  	Training
	[***]	  	[***]	  	[***]	 	[***]
	8.0	  	Equipment, Calibration and Preventative Maintenance
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
		  	[***]	  	[***]	 	[***]
		  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9. 

							
	 	  	 Responsibility
	  	Hospira	 	Revance
Therapeutics
	[***]	  	[***]	  	[***]	 	[***]
		  	[***]	  	[***]	 	[***]
	9.0	  	Process Validation
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	10.0	  	Master Batch Record
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	11.0	  	Production
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10.

							
	 	  	 Responsibility
	  	Hospira	 	Revance
Therapeutics
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	12.0	  	Exceptions/Deviations
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	13.0	  	Lot Number & Expiration Dating Assignment
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	14.0	  	 Compliance of Specifications & Other Pertinent Controlled Documents

& Change Control

	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	15.0	  	Testing & Analysis
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11.

							
	 	  	 Responsibility
	  	Hospira	 	Revance
Therapeutics
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	16.0	  	Samples
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	17.0	  	Release
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	23.0	  	Field Alert, BPDR, Recall & Product Withdrawal1
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	24.0	  	Rejects / Returned Goods.
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	[***]	  	[***]	  	[***]	 	[***]
	 25.0
	  	Performance Reports

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12.

							
	 	  	 Responsibility
	  	Hospira	 	Revance
Therapeutics
	 [***]
	  	[***]	  	[***]	 	[***]
	 26.0
	  	Quality Management
	 [***]
	  	[***]	  	[***]	 	[***]
	 27.0
	  	Records Retention
	 [***]
	  	[***]	  	[***]	 	[***]
	 [***]
	  	[***]	  	[***]	 	[***]

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13.

 REVISION HISTORY 

 

			
	 Revision
	  	 Reason for Change

	 01
	  	First issue

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 14.

			
	 Hospira Worldwide, Inc.

275 North Field Drive
 Lake Forest, IL
60045
	  	 Revance Therapeutics, Inc
 7555 Gateway Boulevard
 Newark, CA 94560

 APPENDIX 1: Product list 

 

					
	 Product Name
	  	 	[	***] 
	 Product Type
	  	 	[	***] 
	 Manufacturing Site
	  	 	[	***] 
	 Stability Storage Site
	  	 	[	***] 
	 Stability Testing Site
	  	 	[	***] 
	 Country(ies) of Distribution/Clinical Trial
	  	 	[	***] 
	 Country of Registration
	  	 	[	***] 

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 15.

 APPENDIX 2: Contact List (page 1 of 2) 

Contacts - Revance Therapeutics 
  

					
	 Function
	  	 Contact

	Quality Assurance	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

			
	Analytical /Stability	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

			
	Manufacturing	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

			
	Program Contact	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 16.

 APPENDIX 2: Contact List (page 2 of 2) 

Contacts - Hospira Worldwide, Inc. 
  

					
	 Function
	  	 Contact
	  	 
	 One2One Global Quality
	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

			
	 Quality - Site
	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

			
	 One2One Analyst - Site
	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

			
	 One2One Global Regulatory Affairs
	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

			
	 Complaints – Corporate
	  	 Name:
 Title:

email:
 Tel:

Fax:
	  	 [***]
 [***]

[***]
 [***]

[***]

			
	 Documentation
	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

			
	 Labeling
	  	 Name:
 Title:

email:
 Tel:
	  	 [***]
 [***]

[***]
 [***]

  
 [ ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 17.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]